Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Conduit

Conduit Holdings Limited

Premium
Information Technology

Conduit is a Bermuda-domiciled, London-listed, pure-play reinsurer launched in December 2020 on a "clean sheet" of roughly USD 1.1bn of IPO equity, explicitly designed to exploit the hardening reinsurance market without legacy reserve exposure from pre-2020 underwriting years. It writes treaty reinsurance only, across three segments — Property (53% of FY2025 GPW), Casualty (32%) and Specialty (15%) — and distributes exclusively through reinsurance brokers to insurers and reinsurers worldwide, with the US the single largest source of business. In five years it has scaled GPW from USD 378.8m (FY2021) to USD 1,243.0m (FY2025), with a lean headcount of 68, no financial debt, a short-duration AA-rated investment portfolio of USD 2.3bn, and a fixed USD 0.36 annual dividend. After a difficult 2025 shaped by the California wildfires and a near-complete turnover of senior management, Conduit is repositioning toward excess-of-loss business, heavier retrocession protection and cycle-managed growth in a softening market, under incoming CEO Christian Dunleavy from March 2027. --- ### Company's own description In its FY2025 Annual Report and the H1 2026 presentation, Conduit describes Conduit Re as a Bermuda-based, multi-line reinsurer with global reach, supporting insurers and reinsurers with their property, casualty and specialty reinsurance needs. It frames its value proposition around cycle management across classes of business, combined with an efficient operating model, as the basis for long-term value creation. The company states that the principal activity of the group is to provide reinsurance products and services to clients worldwide (FY2025 Preliminary Results, note 1). ### Business model Conduit is a capital-intensive risk-transfer business. It earns income from two engines: 1. **Underwriting (reinsurance service result).** Conduit assumes a share of the risk portfolios of primary insurers (cedants) under treaty contracts, receiving premium in exchange for agreeing to pay a share of the cedant's losses. Contracts are written on either a proportional basis (quota share, where Conduit takes a fixed share of premium and losses and pays a ceding commission) or a non-proportional basis (excess of loss, where Conduit pays losses above an attachment point up to a limit). Conduit also writes "quota share of excess of loss" business, in which it takes a proportional share of another reinsurer's or insurer's excess-of-loss book (FY2021 Preliminary Results). 2. **Investment of float and capital.** Premiums are collected ahead of claims payment, and reserves for long-tail casualty business can remain on the balance sheet for years. The float and shareholders' equity are invested in a conservatively managed fixed-income portfolio. Net investment income rose from USD 5.5m in FY2021 to USD 80.7m in FY2025 (H1 2026 presentation), and investment leverage (managed investments and cash divided by equity) has grown from 1.1x to 2.1x. Risk is managed by purchasing outwards reinsurance ("retrocession"), including excess-of-loss programmes, aggregate covers, industry loss warranties and, historically, a sponsored catastrophe bond. ### Revenue model | Revenue component (USD M, FY2025) | Amount | Share of total income | Source | |---|---|---|---| | Reinsurance revenue | 897.1 | 88.3% | FY2025 Preliminary Results | | Net investment income | 80.7 | 7.9% | FY2025 Preliminary Results | | Net realised and unrealised investment gains | 38.8 | 3.8% | FY2025 Preliminary Results | | Total | 1016.6 | 100.0% | Derived | Conduit's revenue is effectively 100% insurance service revenue ("reinsurance revenue" under IFRS 17) plus investment income. The product/service/subscription/licensing taxonomy does not map cleanly onto a reinsurer; the closest analogy is that reinsurance revenue is a recurring, annually renewable contract stream (most treaties renew annually at 1 January, 1 April, 1 June or 1 July), with pricing reset at each renewal. Structural mix by contract type: Conduit started heavily weighted toward quota share in 2021 (it noted this as the main deviation from its IPO prospectus plan in the Q3 2021 trading update). Since H1 2025 management has been deliberately reducing quota share exposure and growing excess of loss, particularly in Property, where excess of loss is expected to reach about 40% of Property GPW in 2026 (Quartr summary of H1 2026 results). ### Value-chain position Conduit sits in the "second tier" of the risk-transfer chain: it does not deal with policyholders. Its customers are insurers and reinsurers (cedants); its distribution partners are reinsurance brokers (the large global reinsurance brokers and specialists). It, in turn, buys retrocession from other reinsurers and capital-market providers. It carries no distribution infrastructure, no claims-handling network for original insureds, and no primary underwriting platform such as a Lloyd's syndicate or MGA. ### Customer types and end-markets **Customers:** primary property and casualty insurers (personal and commercial lines), specialty insurers, Lloyd's syndicates and other reinsurers (via retrocession-style quota share of excess of loss). - **End-markets by class (FY2025 GPW mix, H1 2026 presentation appendix):** Property — commercial 35%, personal 18%; Casualty — general third-party liability 23%, professional liability / financial institutions 6%, auto liability under 1%, other 2%; Specialty — multi-line 6%, energy and power 4%, marine 4%, aviation 1%, cyber 1%, construction and engineering under 1%, other under 1%. **By geography (FY2025 GPW by location):** US about 46%, worldwide-scope contracts about 37%, Europe about 12%, other about 5%. ### Independent characterisation Conduit is best characterised as a sub-scale, mono-line-structure (treaty-only), broker-dependent Bermuda reinsurer that reached about USD 1.2bn of GPW faster than any peer of its vintage, but whose catastrophe-exposed Property quota-share book proved more volatile than intended. The 2025–2026 period represents a second-phase strategy: lower gross volatility through retrocession, a shift to excess of loss, emphasis on Casualty growth with "preferred partners", and capital return through buybacks while the shares trade well below tangible book. Its competitive identity is "nimble, no-legacy, low-cost", but its scale disadvantage against the large Bermudian reinsurers and its leadership churn are the key debates for investors.

RevenueN/A
Employees68
Market CapN/A
Founded2020
Pembroke, Bermuda

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Comunication

Comunication Weaver Co., Ltd.

Premium
Information Technology

| Metric | FY2016 | FY2025 | FY2026 | |---|---|---|---| | Employees (headcount) | 125 | 155 | 160 | Notes: - FY2016: 125 employees, of whom 48 in R&D (Netmanias company profile). - FY2025: 155 per Simply Wall St. Other aggregators show 153 (Investing.com), 165 and 167 (Morningstar). - FY2026 is June 2026: 160 per Catch. THE VC reports 146 based on national pension enrolment (June 2026), down 3% month-on-month. - Average annual salary: KRW 71.1 million (Catch, 2026 data). COWEAVER is a Seoul-based optical transport equipment maker founded in February 2000 and listed on KOSDAQ since December 2001. It designs its own transmission systems: ROADM, packet-optical (POTN), CWDM/WDM, MPLS-TP packet transport (PTN), MSPP, clock-distribution (DOTS) and GPON systems. These are sold almost entirely in Korea. Buyers are the three national carriers (KT, LG U+, SK Broadband/SK Telecom) and public infrastructure operators: KORAIL, Korea Expressway Corporation, KEPCO and the national rail network authority. The company was built by replacing imported transport gear with domestic products. It describes itself as Korea's No. 1 wired optical transmission vendor, though a key rival, Woorinet, claims PTN leadership. Revenue is small and lumpy, tracking carrier capex: it peaked at KRW 113.1bn in 2019, fell to KRW 46.8bn in 2024 and recovered to KRW 62.6bn in 2025. The strategic bet is quantum-safe transport: QKD-linked and PQC-encrypted transmission. The balance sheet is nearly debt-free and the stock trades at roughly 0.3x book. --- ### Company's own description The FY2025 annual report and the corporate website describe Coweaver as a company founded to develop and sell wired and wireless telecommunications equipment. Its core business is the optical transmission equipment that forms the backbone of trunk telecom networks. The company says it developed these systems in-house in a market historically dominated by foreign vendors. It supplies them to the domestic carriers (KT, LG U+, SKT/SK Broadband) and has broadened sales to public institutions and financial institutions (company introduction; FY2025 annual report). The March 2021 KOSDAQ technology analysis report (published under the exchange's investor-information programme) gives more detail. It says Coweaver: - supplies optical transmission equipment to domestic carriers; - is expanding into public and financial customers; - developed IP network equipment for large-volume data and supplied it to LG U+, KT and SK Telecom; - commercialised transport ("전달망") network equipment; - participates in 5G infrastructure build-out; - works on passive optical subscriber networks. The same report lists KORAIL, Korea Expressway Corporation and KEPCO as public-sector accounts. ### Independent characterization Coweaver is a domestic, single-segment, tender-driven telecom capital-equipment vendor. Its economics depend on: 1. the timing of Korean carrier transport-network capex cycles (2G/3G, LTE, 5G, now 5G-SA and AI-traffic backbone upgrades); 2. public-utility network modernisation, such as KEPCO substation communications and rail and highway networks; 3. its ability to win unit-price and single-supply contracts against a small group of domestic rivals (Woorinet in PTN/quantum transport; HFR and others in adjacent access/fronthaul) and, in high-capacity WDM, against global vendors. The company is effectively a domestic "system integrator-manufacturer". It designs boards, software and network-management functions in-house. It sources optics such as coherent transceivers from component suppliers (for example, OIsolution under a December 2024 MOU) and assembles and supports systems for carriers. ### Business and revenue model | Dimension | Characterization | Evidence | |---|---|---| | Revenue type | One-off product sales (hardware plus embedded software), plus merchandise resale and some service | Latest product-mix data (AlphaSquare): products about 92.7% of revenue, merchandise ("상품") 7.3% | | Subscription / licensing | None disclosed | — | | Contracting | Single-supply contracts and unit-price contracts with carriers and public bodies, disclosed when material | Orders of KRW 13.4bn (Dec 2022), 7.9bn (Apr 2023) and 7.0bn (Oct 2023) (Stockopedia/Reuters briefs) | | Seasonality | Strongly back-end loaded (carrier year-end acceptance) | Q4 2025 revenue KRW 26.36bn out of FY2025 KRW 62.6bn, i.e. about 42% in one quarter (Investing.com, period ending Dec 2025) | | Order backlog | Disclosed in periodic reports | KRW 18.44bn at end-H1 2023 (The Elec, citing the H1 2023 report). | | Geography | Domestic | H1 2023 report: 100% domestic sales (The Elec). Q2 2026: wired communications is 100% of segment revenue (Butler) | ### Value-chain position | Layer | Players | Coweaver role | |---|---|---| | Optical components (lasers, transceivers, WSS) | OIsolution, Lumentum, Coherent, others | Buyer. Coweaver also ran national R&D on optical switches and wavelength-selective switches (2024) | | Transport systems (WDM/ROADM, POTN, PTN, MSPP) | Coweaver, Woorinet, global vendors (Nokia, Ciena, Huawei, etc.) | Core position: system design, software, integration | | Security overlay (QKD, PQC, encryptors) | SKT/IDQ, Woorinet, EYL, Coweaver | Integrates QKD/PQC into transport equipment | | Network operators | KT, SK Broadband/SKT, LG U+; KEPCO, KORAIL, Korea Expressway Corp. | Customers | ### Customer types and end-markets | Customer type | Named customers (disclosed or reported) | End-market | |---|---|---| | Fixed and mobile carriers | KT, LG U+, SK Broadband, SK Telecom | Backbone, metro and mobile backhaul / 5G transport | | Public utilities and infrastructure | KEPCO (substation optical terminals), KORAIL, Korea Expressway Corporation, Korea Rail Network Authority | Private networks for power grid, rail and road | | Financial institutions / state-owned corporates | Not named individually | Dedicated secure leased-line networks | | Government (B2G) | 45 B2G contracts recorded by THE VC (counterparties not itemised) | Public networks, R&D | Customer concentration percentages (share of revenue from KT, LG U+, SKB and so on) are not publicly disclosed in reviewed sources.

RevenueN/A
Employees160
Market CapN/A
Founded2000
Seoul, South Korea
Compagnie

Compagnie d'Entreprises CFE SA

Premium
Information Technology

(FY2023 ≈3,100 FTE per KBC Securities commentary on Bolero; FY2025 uses Google Finance/TipRanks figure; see discrepancy above.) CFE is a mid-sized Belgian multidisciplinary construction-and-development group, majority-controlled by the Antwerp holding Ackermans & van Haaren, that has reinvented itself since spinning off DEME in mid-2022. It combines four activities: real-estate development (BPI Real Estate in Belgium, Luxembourg and Poland), multitechnics (VMA building technologies and industrial automation; MOBIX rail and energy infrastructure), general construction and renovation (BPC, MBG, Van Laere, CLE, CFE Polska, Wood Shapers) and a small portfolio of co-controlled infrastructure investments (Belgian offshore wind, Vietnamese industrial zones via Deep C, Belgian battery storage via BSTOR). Its pitch is "integrated lifecycle solutions" — develop, build, equip and maintain — aimed at sustainable buildings, smart industry and energy-transition infrastructure. With ~EUR 1.0–1.2 bn revenue, a EUR 1.6 bn order book, a net cash balance sheet and margins recovering toward 4%+ EBIT, CFE is a disciplined, low-valuation, controlled small-cap whose upside is concentrated in Kennedy Park (Luxembourg), VMA growth and Deep C. --- ### Company's own description In its latest regulated releases, CFE describes itself as an integrated multidisciplinary group focused on attractive growth markets in Belgium, Luxembourg and Poland, active in four segments (real-estate development, multitechnics, construction & renovation, and investments), offering end-to-end solutions "from acquisition to maintenance," and positioning sustainability, innovation and societal impact as differentiators [FY25-PR; H1-26-PR]. The H1 2026 release names its target growth markets as energy-efficient buildings, quality housing, smart industry, digitalisation (data centres) and energy-transition infrastructure [H1-26-PR]. The FY2025 outlook additionally highlights renovation and energy-performance upgrades of existing buildings, technically complex construction for industry, hospitals, defence and data centres [FY25-PR]. ### Business model and revenue model | Revenue type | Approx. share of FY2025 consolidated revenue | Characterisation | |---|---|---| | Construction & renovation contracts | 65.6% (EUR 683.4 M) | Lump-sum and cost-reimbursable building contracts; offices, housing, hospitals, schools, industrial, data centres | | Multitechnics contracts and services | 28.9% (EUR 301.4 M) | Electrical/HVAC installation (project), maintenance (recurring), industrial automation (project), rail and utility works (frame contracts) | | Real-estate development sales | 7.4% (EUR 76.7 M) | Residential and office developments, block sales to investors, land/plot sales | | Holding/investments | 0.3% before eliminations (EUR 2.7 M) | Central services; investment returns flow through equity-accounted income (not revenue) | | Inter-segment eliminations | -2.2% (EUR -22.7 M) | Intra-group contracting (e.g., group construction for BPI projects) | CFE's revenue is overwhelmingly project/contract revenue recognised over time (IFRS 15 percentage-of-completion) in construction and multitechnics, supplemented by development margins (sale of real-estate projects, in Belgium/Luxembourg largely recognised progressively under VEFA-type sales, in Poland on delivery) and equity-accounted income from co-controlled investments. Source: FY25-PR segment note. Product vs. service vs. subscription vs. licensing mix: CFE has no licensing or subscription revenue of note; recurring service revenue is concentrated in VMA Maintenance (crossed EUR 25 M for the first time in 2023 [FY23-PR], with double-digit growth reported in H1 2026 [H1-26-PR]) and multi-year DBFM/maintenance contracts (e.g., MOBIX's LuWa public-lighting contract). Management explicitly targets a higher share of recurring revenue [FY25-PR CEO statement]. ### Value-chain position CFE spans the building value chain: land acquisition and permitting (BPI), design optimisation and general contracting (C&R subsidiaries), technical installations and smart-building management (VMA, VMANAGER), long-term maintenance (VMA Maintenance), and specialist infrastructure (MOBIX: rail signalling, catenary, track, cabling, lighting). It does not manufacture building materials at scale; its timber prefabrication (LTS production units at Moorslede) was sold in 2025 [FY25-PR], and another production site at Marche-en-Famenne was sold in H1 2026 [H1-26-PR]. ### Customer types and end-markets **Public authorities and public infrastructure owners:** Infrabel (Belgian rail), Lantis/Flemish authorities (Oosterweel Antwerp ring), Province of Liège, Walloon Region (LuWa lighting), European Commission (EQ building), Flemish Government (ZIN), NATO/SHAPE (600 homes at Mons), university hospitals (UZ Leuven, UZ Gent). **Private developers and investors:** Befimmo/Brookfield, AG Real Estate, Matexi, ION Residential, Ethias, KPMG Luxembourg, Linklaters, PwC Luxembourg. **Industrial clients:** INEOS (Project One ethane cracker), UCB, automotive OEMs via VMA (VW, JLR projects cited in FY23-PR), MBDA (defence plant in Poland), data-centre operators (LCL Brussels-North). **Retail homebuyers:** BPI residential programmes in Belgium, Luxembourg and Poland. ### Independent characterisation Analytically, CFE is best understood as a Belgian general contractor with an attached developer and a technical-services platform, plus a "hidden" infrastructure investment book. The construction business provides scale, cash (strong negative working capital — net cash of EUR 285.8 M inside the C&R segment at end-2025 [FY25-PR]) and pipeline for BPI; BPI provides higher-margin earnings but is cyclical and permit-sensitive; VMA is the most structurally attractive franchise (data centres, hospitals, maintenance); MOBIX is a chronic underperformer tied to Infrabel budgets and a loss-making DBFM contract. The investment segment (Deep C, Green Offshore, GreenStor) contributes volatile but meaningful equity-accounted profit and is co-owned 50/50 with AvH, which limits CFE's autonomy over those assets.

Revenue$1.2B
Employees2,712
Market CapN/A
Founded1880
Brussels, Belgium
COMMAX

COMMAX Co., Ltd.

Premium
Information Technology

COMMAX is one of Korea's oldest specialists in building-entry communications. It began as a telephone and intercom maker in 1968 and evolved into a supplier of video door phones, apartment wall pads, home-network and smart-home IoT systems, access control, CCTV and nurse-call systems. Its domestic franchise rests on apartment new-build projects, where press reports attribute roughly 30% of the Korean wall-pad market to the company. A long export history to 100–130 countries gives it an unusually international footprint for a small-cap. Since 2021, a construction downturn, low-priced Chinese competition and internal-control failures pushed the company into five straight years of operating losses. An FY2023 audit disclaimer followed, and trading has been suspended since March 2024. In February 2026, boiler and HVAC leader Kyung Dong Navien acquired 80.77% for KRW 32 bn. The repositioned thesis is a restructuring story: COMMAX as the access-control and wall-pad hardware layer of Navien's smart-home and North American building-technology ecosystem, conditional on retaining its KOSDAQ listing. --- ### What the company does COMMAX designs, manufactures and sells communication, access and security equipment for residential and non-residential buildings. Third-party business descriptions derived from its filings group the portfolio into the following lines: - wall pads and video phones (in-unit terminals) - door cameras, door stations and audio door units - lobby phones, including entrance stations, multi-button audio stations, AI home IoT lobby phones and audio panels - IoT devices, including IR and PIR sensors, smart curtains, smart repeaters, temperature and humidity sensors, gas breakers, motion and magnetic sensors and network switches - guard stations and security-office equipment - digital and biometric door locks - CCTV (analog, IP, software, and parking management and guidance) - handset and hands-free interphones - nurse-call systems (extension devices, bed-head consoles, corridor lights, operating-room call systems and foot switches) - household and floor distributors, CCTV distributors, SIP servers and switches Products are exported to about 130 countries according to the company profile carried by Investing.com and Simply Wall St. ### Business model and revenue model **Product-dominated model:** Revenue is overwhelmingly hardware sales. Butler's segment breakdown of DART data shows "Smart Home Solutions" at about 81% and "ACC (accessories) and other" at about 19% of Q2 2026 revenue. Service revenue (installation and after-sales) existed historically through the 100%-owned after-sales subsidiary COMMAX CS, which was merged into the parent on 1 July 2026. Subscription or licensing revenue is not separately disclosed and appears immaterial. **Project-based domestic sales:** In Korea, wall pads and home-network systems are specified and procured at the apartment-complex level. Contracts run through construction companies and developers, so revenue recognition follows construction schedules. Global Epic and Greened both describe COMMAX's domestic revenue as heavily dependent on apartment supply, which explains its sensitivity to the 2022–2025 Korean housing downturn. **Distributor-based export sales:** Overseas, COMMAX historically sold standardised video door phones and intercoms through distributors in more than 100 countries. A 2013–2015 initiative added company-run "COMMAX Plaza" security retail outlets in Korea (Seoul, Gimhae, Ulsan). **Retrofit and replacement:** Management and the acquirer now emphasise replacement demand in existing apartments, reflecting both a weak new-build pipeline and the regulatory push for home-network security upgrades. ### Value-chain position COMMAX is a vertically integrated original-brand manufacturer. It performs in-house R&D (hardware, firmware and integration software), produces largely through its Chinese manufacturing subsidiary Tianjin Zhongyuan Electronics Co., Ltd. (Tianjin, PRC), sells under the COMMAX brand, and historically provided after-sales service through COMMAX CS. Upstream it buys electronic components, displays and camera modules. Downstream it supplies construction companies, developers, systems integrators, distributors, hospitals (nurse call) and end-customers through retail. A notable 2025–2026 development is COMMAX's position as the sole hardware supplier to SmartONE Solutions Inc., a Canadian smart-building platform. Through the NaviComm consortium, this relationship has become an equity position. ### Customer types and end-markets | Customer type | End-market | Products | |---|---|---| | Construction companies and developers (Korea) | New-build apartments | Wall pads, home-network systems, lobby phones, door cameras, parking guidance, CCTV | | Apartment owners' associations / management offices (Korea) | Replacement and retrofit | Wall pads, lobby phones, guard stations, IoT devices | | Hospitals and care facilities | Healthcare | Nurse-call systems, bed-head consoles, corridor lights | | Commercial building owners and offices | Commercial real estate | Access control, CCTV, intercoms | | Overseas distributors and installers | Residential and light-commercial abroad | Video door phones, intercoms, door locks | | Platform partners (e.g., SmartONE / NaviComm, Canada) | North American multifamily smart buildings | OEM hardware for platform deployments | | Retail end-users | Single-family and small buildings | Door phones, door locks, CCTV | ### Company's own description versus independent characterisation The company's English-language corporate description, as carried by third-party profiles, presents COMMAX as a smart-home specialist founded in 1968 as Central Electronic Industry. It says COMMAX leads global markets with technology spanning interphones, video phones, smart-home systems and security solutions, and creates "value and safety of life" for customers. In the H1 2026 half-year report, management said it had adopted a strategy prioritising qualitative over quantitative growth and that the restructuring was stabilising the financial structure (reported by Bloter, 18 Aug 2026). **Independent characterisation.** COMMAX is a sub-scale, hardware-centric building-communications OEM. It has a strong legacy brand and installed base in Korean apartments, but it lost pricing power and cost competitiveness between 2021 and 2025. Revenue fell 40% between FY2022 and FY2025 (KRW 156.0 bn to KRW 85.1 bn) and gross margin compressed to single digits in FY2025. Its strategic value now lies less in standalone earnings power than in three assets that a larger strategic owner can monetise: - its installed base and specification relationships with Korean builders - its access-control and wall-pad product stack - its role as hardware supplier to the North American smart-building platform now controlled by the Navien group

Revenue$0.1B
Employees130
Market CapN/A
Founded1968
Seongnam, South Korea
Combined

Combined Motor Holdings Limited

Premium
Information Technology

CMH is a KwaZulu-Natal-headquartered, founder-led automotive retail and mobility group. It operates only in South Africa through three reportable segments: motor retail and distribution, car hire, and financial services. Motor retail generates about 93–94% of revenue. It runs 38 multi-franchise dealerships representing 31 brands across Gauteng, KwaZulu-Natal and the Western Cape. Alongside the dealerships sit a growing import-distribution arm (Foton SA light commercial vehicles; Proton SA, now being wound down) and an aftermarket parts franchisor, Mandarin Parts Distributors. First Car Rental is one of South Africa's larger independent car-hire brands, with a fleet of more than 7,500 vehicles across 53 branches. It earns a disproportionate share of group profit relative to its revenue. Financial services comprise insurance underwriting cells and vehicle-finance joint ventures with two banks. Management is conservative and long-tenured: the CEO has been on the board since 1976. The balance sheet carries surplus cash (R1.15bn at FY2026), which is now being redeployed into owner-occupied dealership property. --- ### Company's own description (2026 IAR, paraphrased) The 2026 IAR describes CMH as an investment holding company that does not trade itself. All operations are carried out through subsidiaries with significant interests in motor retail/distribution, car hire and financial services. The report states that the group operates only in South Africa and employed 2,712 people at year-end. It describes the financial focus as generating growth, shareholder returns and strong free cash flow, backed by a strong statement of financial position and regular dividends. The mission statement commits the group to customers, suppliers, employees and shareholders, and sets the shareholder aim as consistent, meaningful growth in earnings and dividends commensurate with risk. ### What the company does: segment by segment **Motor retail and distribution (FY2026: about 93–94% of revenue; 49% of segment pre-tax profit)** **Retail dealerships:** 38 dealerships representing 31 brands. Each has new- and used-vehicle sales, finance and insurance (F&I) specialists, a workshop and a parts department. Several sites carry two or more franchises. The brand mix covers passenger, light commercial and heavy commercial vehicles in both volume and luxury categories. The segment employs 2,119 people (2026 IAR). **Import/distribution:** Foton SA imports and distributes a range of light commercial vehicles plus parts and accessories. It sells through 15 CMH and 48 independent dealers, with a target of 70 dealers during FY2027. Proton SA imports Proton and Saga passenger vehicles; this business will close once remaining stock is sold. **Aftermarket parts:** Mandarin Parts Distributors (MPD) imports aftermarket parts, focused on out-of-warranty Chinese- and Indian-brand vehicles. It sells through a large in-house outlet near Pretoria and a franchise network. The IAR gives 28 independent franchisees; the analyst presentation gives 29. **CMH Fleet Solutions:** a B-BBEE Level 2 fleet-purchasing channel. It serves fleet owners who need an empowerment-favourable supplier. **Car hire (FY2026: 29% of segment pre-tax profit)** - First Car Rental (CMH Car Hire (Pty) Ltd) offers short- and long-term rental from no-frills to luxury vehicles. It has more than 7,500 vehicles, 53 branches (17 airport locations listed) and 508 employees (2026 IAR). Customer channels include corporate, leisure and inbound tourism, insurance-replacement rentals, and an alliance with low-cost airline FlySafair. The business is vertically integrated with the dealerships: it targets selling at least 50% of retired fleet through group used-vehicle outlets. **Financial services (FY2026: 13% of segment pre-tax profit)** - Insurance underwriting cells cover products sold with new and used vehicles: death, disability, dread disease, retrenchment cover, and vehicle and component warranties. Administration is outsourced (cells administered by Traficc per the FY2026 analyst presentation). - Vehicle-finance joint ventures with two major finance houses. The banks are not named in the documents reviewed. Both divisions are managed by external providers. **Corporate services and other (FY2026: 9% of segment pre-tax profit, derived)** - Corporate services; National Workshop Equipment (workshop lifting, lubrication and diagnostic equipment); "CMH Green" waterless car-wash systems; office consumables; and Rokkit Digital Agency (in-house digital marketing). These units employ 85 people. ### Business model and revenue model **Product vs. service mix:** Revenue is dominated by vehicle sales. In FY2025, motor retail/distribution external revenue was R12,223m of R13,252m (92.2%). Car hire contributed R830m (6.3%), financial services R140m (1.1%: insurance R124m, other R16m), and corporate/other R58m (0.4%) (H1 FY2026 interim report, FY2025 comparative column). In FY2026, motor retail/distribution external revenue was about R14.68bn of R15.71bn (about 93–94%, per Daily Investor citing the 2026 IAR segment note). **Profit mix differs sharply from the revenue mix:** Car hire and financial services together produced 42% of segment pre-tax profit in FY2026 on roughly 6–7% of revenue. The group's earnings are therefore much less dependent on new-vehicle gross margins than its revenue suggests. **Subscription/licensing:** None. Recurring, annuity-like income comes from insurance premiums (recognised over policy terms), workshop and parts aftersales, and rental contracts. **Value-chain position:** CMH spans several links: importer/distributor (Foton, Proton), franchised retailer, aftermarket parts franchisor (MPD), rental fleet operator (which also generates used-car supply), and F&I intermediary/underwriter. **Customer types:** retail consumers; SMEs (the core of Foton LCV demand); corporate and government fleet buyers (Fleet Solutions); inbound tourists, business travellers and insurance-replacement renters (First Car Rental); and independent dealers and parts franchisees (wholesale). **End-markets:** South African new and used passenger and light commercial vehicle retail; heavy commercial (Foton Trucks site); vehicle rental; vehicle credit and insurance; the automotive aftermarket. ### Independent characterisation CMH is best understood as a cash-generative, low-capital-intensity South African motor retailer with an embedded rental business. The rental arm earns higher returns on revenue and acts as a natural used-vehicle feeder. Its structural strategic shift since about FY2023 has been to rebuild the dealership network around fast-growing Chinese- and Indian-sourced brands. These made up about 55% of national new-vehicle sales in calendar 2025. Within the group, Suzuki became the top seller in FY2026, and Foton, Mahindra and Haval/GWM ranked in the top six by volume. The Foton import-distribution contract is the most important new profit pool, because distribution margins exceed retail margins. Its weaknesses are concentration in three South African provinces, structurally thin retail margins (about 1.3–1.8% pre-tax), and governance features typical of a founder-controlled company.

Revenue$0.9B
Employees2,712
Market CapN/A
Founded1976
Umhlanga Ridge, South Africa
Coil

Coil S.A./N.V.

Premium
Information Technology

COIL describes itself as the world's largest anodiser for the building and industrial sectors. It specialises in continuous coil-to-coil anodising of aluminium flat-rolled products, supplemented by batch anodising of sheets and panels. Its plants in Landen (Belgium) and Bernburg (Germany) operate continuous lines that, according to the company's corporate profile, can treat aluminium up to 2,000 mm wide and up to 5 mm thick, a dimensional envelope it presents as unique. About 80–86% of revenue is tolling: anodising metal owned by rolling mills and distributors. The balance comes from "packaged" sales, in which COIL supplies pre-anodised ALOXIDE® metal directly to architects, façade fabricators and industrial users. The company built a brief technology-licensing revenue line in China in 2024. Since 2023 it has lost money, breached bank covenants and needed an emergency reserved capital increase. In late 2025 control passed to a new Clarke-led shareholder group, and the company is now executing a cost-led turnaround. --- ### Company's own description In every recent release (FY2023–H1 2026), COIL describes itself as the world's leading anodiser in the building and industrial sectors, trading under the ALOXIDE brand. It explains anodising as an electrolytic process that grows a natural, protective oxide layer on aluminium. That layer can be coloured in UV-resistant finishes and improves corrosion resistance and functional properties, while keeping aluminium's rigidity, strength-to-weight ratio, non-magnetic behaviour and full recyclability by simple re-melting. The company lists architecture, design, manufacturing and automotive as its application fields. It frames its model as industrial value creation based on unique know-how, operational excellence, the quality of its investments and the expertise of its people (FY2025 annual results press release, 30 April 2026). Third-party data providers (FMP and Simply Wall St, drawing on company materials) describe COIL as providing anodising services on aluminium flat-rolled products in coil form, sheets and panels in Europe. They list end uses in architecture, public works, welded tubes, automotive, consumer goods, medical, aerospace and signage, and brands including ALOXIDE, X-ICONIC, X-WALL, X-BOND, X-FLEX, X-DECO, X-TECH, X-TREAD, X-3D, X-MED and X-SKY. These sources say COIL serves customers through a network of distributors. ### Business model and revenue model COIL reports three revenue streams: 1. **Tolling sales** ("sous-traitance"). COIL anodises aluminium coil owned by the customer, typically a rolling mill or a metal distributor, and charges a conversion fee. The metal stays on the customer's balance sheet, so revenue reflects only the anodising value-add. This stream was 80.6% of FY2025 sales (EUR 15.64 million) and 86% of H1 2026 sales (about EUR 7.7 million). 2. **Packaged sales** ("ventes packagées" / "package offers"). COIL supplies continuous-anodised aluminium directly to the end customer, with both the anodising and the metal included in the price, according to the footnote definition in the 29 January 2026 release. These are project-driven, mostly high-end architectural façades in Europe and Asia. FY2025: EUR 3.77 million (19.4% of sales). H1 2026: EUR 1.2 million (14%). 3. **Licensing and royalties.** This stream comes from the February 2024 technology and brand licence in China. It produced EUR 2.0 million in FY2024 (H1 2024 only) and nothing in FY2025. China is excluded from the 2026 budget. There is no subscription revenue. Analytically, the model is a fixed-cost-heavy industrial service. The company itself stresses that variable costs are only about 36% of sales (FY2023 annual results release, 30 April 2024), so volume swings flow strongly into EBITDA. ### Value-chain position COIL sits between primary rolling mills and distributors upstream and façade fabricators, panel makers, architects and OEM manufacturers downstream. In tolling, it effectively acts as an outsourced finishing step for the mills. Management describes the 2026 strategy as developing tolling in partnership with the main European rolling mills (H1 2026 revenue release, 29 July 2026). In packaged sales, COIL takes metal-price risk and sells a finished architectural product under its own brand. ### Customer types and end-markets | Customer type | Revenue stream | Notes (source) | |---|---|---| | European aluminium rolling mills | Tolling | Strategic partners in the turnaround model (H1 2026 release). A one-off rolling-mill order linked to a Chinese project boosted H1 2024 (29 Jan 2026 release). | | Metal distributors / stockists | Tolling | Their inventory behaviour drove the 2023–2025 tolling decline: destocking when LME prices fell, restocking when prices rose (FY2023 and FY2025 releases). | | Architects, façade contractors, project owners | Packaged | High-end architectural projects in Europe; Asian project pipeline; first significant Saudi Arabian project delivered in late 2025. | | Industrial / OEM users | Tolling and packaged | Automotive, consumer goods, design and luxury brands (the 2020 ALOXIDE website release cites long-standing use by high-end luxury brands). | | Licensee (China) | Licensing | Unnamed Chinese company; exclusive, perpetual licence (14 Feb 2024 release). | | New partner in India | Packaged / tolling (not specified) | First order recorded in 2025 (29 Jan 2026 release). | ### Independent characterisation COIL is a sub-scale, single-process specialist with a genuinely niche technical position: wide, continuous anodising. That position was badly exposed by three things at once: European construction weakness, distributor destocking after the 2021–2022 aluminium price spike, and, from 2023, a new entrant in European continuous anodising. Revenue fell from EUR 29.8 million in FY2019 to EUR 19.4 million in FY2025, about -35%. With a cost base built for higher throughput, EBITDA went from EUR 6.3 million (24.8% margin) in FY2021 to EUR -1.1 million in FY2025. The China licence was a one-year relief, not a structural fix. The business is now controlled by a new reference shareholder group and run day-to-day by long-serving internal managers. It is pivoting to a leaner, tolling-centred model with flexible line utilisation.

RevenueN/A
Employees110
Market CapN/A
Founded1972
Landen, Belgium
Cofinimmo

Cofinimmo SA

Premium
Information Technology

| Field | Detail | |---|---| | Entity profiled | Aedifica SA/NV (absorbing company of Cofinimmo SA/NV) | | Legal form | Public limited liability company; public regulated real estate company (RREC / SIR / GVV) under Belgian law | | Registered office / HQ | Rue Belliard 40 (box 11), 1040 Brussels, Belgium | | Enterprise number | 0877.248.501 (RLE Brussels) | | Incorporation | 7 November 2005, Belgium | | Listings | Euronext Brussels (since 2006 IPO) and Euronext Amsterdam (since November 2019) | | Ticker | AED (Euronext Brussels/Amsterdam); AOO (German venues) | | ISIN | BE0003851681 | | Index membership | BEL 20 (since March 2020, weighting ~4.7% at 30.06.2026), BEL ESG, EPRA Europe (~2.9% weighting), EPRA Belgium (~34.6%), GPR 250, Stoxx Europe 600 | | Fiscal year end | 31 December | | Shares outstanding | 92,632,604 (after 1 July 2026 merger issuance) | | Share price (approx.) | ~EUR 62.30 (Lang & Schwarz weekend quote, 18 Oct 2026; secondary source) | | Market capitalisation (derived) | ~EUR 5.77 bn (92.63m shares × EUR 62.30). Note: one secondary source quoted EUR 5.2 bn on 16 Oct 2026; the discrepancy likely reflects a stale share count. Company-reported market cap was EUR 5.89 bn at 30.06.2026 on 83.47m shares at EUR 70.60 | | 52-week range | EUR 60.35 – 80.05 (secondary source, 16 Oct 2026) | | Employees | Aedifica standalone: ~127–131 (aggregator data, pre-merger). Combined headcount after absorbing Cofinimmo's team: not publicly disclosed | | Statutory auditor | Aedifica: not confirmed in this research (H1 2026 report contains a limited-review auditor's report; name not captured). Legacy Cofinimmo: KPMG Réviseurs d'Entreprises, represented by Jean-François Kupper (Cofinimmo FY2025 press release, 20.02.2026) | | Website | www.aedifica.eu (legacy: www.cofinimmo.com) | | Credit ratings | S&P: BBB+ / stable / A-2 (upgraded March 2026, reconfirmed 20 July 2026). Moody's: A3 / stable, first-time issuer rating (reported 15 Oct 2026 by secondary sources; see Section 21) | ### Legacy entity (for reference) | Field | Detail | |---|---| | Legal name | Cofinimmo SA/NV | | Enterprise number | 0426.184.049 (Brussels Register of Legal Entities) | | Founded | 1983 | | HQ | Avenue de Tervueren / Tervurenlaan 270, Brussels ("The Gradient" building) | | Former listing | Euronext Brussels, ticker COFB, ISIN BE0003593044; BEL 20 constituent | | REIT regimes | Belgian RREC, French SIIC, Dutch FBI, Spanish SOCIMI (per company and press descriptions) | | Shares | 38,096,217 issued at 31.12.2025 | | Market cap at 31.12.2025 | EUR 3,017 m (share price EUR 79.20) | | Last CEO / CFO | Jean-Pierre Hanin (CEO) / Jean Kotarakos (CFO) | | Status | Delisted 1 July 2026; absorbed by Aedifica | | Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Aedifica employees (headcount) | — | 131 | 127 | Note: 2024–2025 headcounts come from data aggregators (roic.ai, Investing.com) and are not company-verified; Cofinimmo headcount was not captured in this research. Aedifica, following its absorption of Cofinimmo, is Europe's largest listed healthcare real estate investment trust by portfolio value. At 30 June 2026 it owned a EUR 12.5 bn portfolio of 1,723 properties, including a EUR 11.1 bn healthcare book of 924 care properties housing roughly 67,400 residents and 12,900 children across nine countries: Belgium, Germany, Finland, the UK, the Netherlands, France, Ireland, Spain and Italy. Its business model is long-lease, largely triple- or double-net rental to professional care operators, indexed to inflation, with a 15-year WAULT and 99.1% occupancy. The group carries two non-core legacy segments from Cofinimmo: Brussels offices (EUR 874 m) and the Pubstone pub portfolio leased to AB InBev (EUR 468 m). With BBB+ (S&P) and A3 (Moody's) ratings, a 1.9% average cost of debt and EUR 16 m targeted run-rate synergies, the group is positioned as the scale consolidator in a fragmented, demographically driven European care property market. --- ### What the company does Aedifica is a specialised property investor and developer. It acquires, develops (mostly through pre-let development partnerships), owns and manages real estate used for care. It leases these assets on long-term contracts to private, non-profit and public operators. It does not provide care services itself; operating risk sits with tenants, while Aedifica bears property, re-letting, tenant-credit and valuation risk. After absorbing Cofinimmo, the group has three reportable activity lines: 1. **Healthcare real estate** (89% of total portfolio fair value; ~88% of contractual rents at 30.06.2026). Sub-types by fair value of the total portfolio: elderly care homes 60%, mixed-use elderly care 13%, cure centres (acute, rehabilitation and psychiatric clinics) 7%, childcare centres 3%, senior housing 2%, disabled-care facilities 2%, other care 2%. 2. **Offices** (7% of fair value; EUR 874 m; 23 sites, all in Belgium, largely Brussels CBD), inherited from Cofinimmo. 3. **Distribution networks** (4% of fair value; EUR 468 m; 776 sites), mainly the Pubstone portfolio of pubs and restaurants in Belgium (577 sites) and the Netherlands (185 sites) leased to AB InBev. Source: Aedifica 2026 Half Year Financial Report (01.09.2026). ### Business and revenue model | Revenue dimension | Characterisation | |---|---| | Revenue type | ~100% rental income (lease/"subscription-like" contractual rent); minor finance-lease interest income, development interest and writeback of sold lease receivables | | Product vs service vs licensing | No product, service or licensing revenue in the conventional sense; revenue is real-estate rent | | Contract structure | Long leases. Triple-net (operator bears operating costs, maintenance and vacancy) typical in Belgium, UK, Ireland and Spain, and often the Netherlands and Italy. Double-net (owner keeps roof, structure and facade) typical in Germany, Finland and France | | Indexation | Annual CPI-linked indexation, usually on the contract anniversary date. H1 2026 like-for-like rental growth of 1.7% was made up of +1.9% indexation, +0.2% reversion and contingent rents, and −0.4% FX | | Lease duration | WAULT 15 years for total portfolio, 16 years for healthcare (30.06.2026) | | Occupancy | 99.1% total; 99.7% healthcare (EPRA methodology, 30.06.2026) | | Gross yield | 6.1% on fair value (healthcare 6.0%, offices 6.3%, distribution 7.4%) | ### Value-chain position Aedifica sits between capital markets (equity, bonds, bank debt, commercial paper) and care operators. It provides long-dated real-estate capital that lets operators run asset-light models. It increasingly acts as a developer-owner: the committed investment programme was EUR 531 m at 30.06.2026, of which EUR 268 m already spent. These are mostly pre-let new builds in Finland, Spain, Ireland, Germany and the UK, with a targeted initial yield on cost of 6–6.5% (actual pipeline average 5.8% after inheriting legacy Cofinimmo Spanish projects). ### Customers and end-markets **Customers:** About 190 tenant groups (Aedifica H1 2026). Largest exposures by contractual rent: Clariane 12%, Colisée (incl. Armonea) 7%, AB InBev 4%, Emeis 4%, DomusVi 3%, Emera 3%, Azurit Rohr 3%, Vulpia 3%, Maria Mallaband 2%, Finnish municipalities/wellbeing services counties 2%. Others account for 57%. **End-markets:** European elderly care (dominant), childcare (Finland), disabled care, acute and rehabilitation care (France, Belgium), mental health, plus Brussels office space and Benelux hospitality (pubs). **Ultimate demand driver:** the over-80 population in the EU and UK, which the company puts above 31 million in 2025 and expects to double to over 60 million by 2060. ### Company's own description (paraphrased) In its latest reporting, Aedifica describes itself as a Belgian REIT focused on European healthcare property, especially elderly-care housing. It frames the Cofinimmo merger as creating Europe's leading healthcare REIT, with lower capital costs and sustainable EPS growth as the main value-creation levers (Aedifica H1 2026 report). Cofinimmo's last self-description (FY2025 release) presented it as a 40-year-old owner of care, living and working spaces under the tagline "Caring, Living and Working – Together in Real Estate", with healthcare in nine countries as its core. ### Independent characterisation Analytically, the combined group is a pure-play European healthcare landlord with a non-core diversified tail of about 11% of portfolio value (offices plus pubs). This tail is a legacy of Cofinimmo's history as Belgium's largest diversified REIT. The investment case rests on three things: 1. Inflation-indexed, very long contractual cash flows. 2. A funding-cost advantage from investment-grade ratings and scale. 3. Disciplined capital recycling out of non-core assets. Its key sensitivities are operator health, especially Clariane and Colisée/Armonea, together about 19% of rent; refinancing costs as legacy cheap hedges roll off; and the trading discount to NAV, which governs whether equity-funded growth is accretive.

RevenueN/A
Employees127
Market CapN/A
Founded1983
Brussels, Belgium
THECODI

THE CODI Co., Ltd.

Premium
Information Technology

THE CODI is a Cheonan-based micro-cap equipment and components maker. It began as a Samsung-qualified supplier of semiconductor and flat-panel-display process tools: wafer cleaning, photoresist coating and developing, back-end bonding, and the hot-plate/cool-plate (HP/CP) glass-drying units it says it has supplied exclusively to Samsung Electronics since 2010. Since 2017 it has been reshaped repeatedly by changes of control. It pivoted into a "bio platform" (subsidiaries PharmaWorks and Cellforium). It absorbed a 1973-founded coil/transformer maker (Daeshin Electronics, merged July 2024), plus small insulation and electrical-equipment companies. It also consolidated real-estate development vehicles that now carry about KRW 39.5 bn of development land on its balance sheet. The core equipment business is sub-scale: consolidated revenue was KRW 25.3 bn in FY2025, with persistent operating losses since 2016. Leverage is high (liabilities about 5.7x equity at FY2025, about 14.8x at June 2026). A contested, repeatedly delayed change of control is tied to a proposed pivot into robotics and AI. The equity is best characterised as a governance-driven special situation rather than an equipment growth story. --- ### Company's own description (from DART filings and IPO materials, paraphrased) The company describes itself, in its filings and vendor-reproduced business summaries, as a manufacturer and seller of semiconductor equipment, LCD equipment and OLED equipment, established in July 1999. It names PharmaWorks and Cellforium as its principal subsidiaries and says most revenue comes from the semiconductor division. As a new business, it plans to build an "open-innovation bio platform." Under this platform it would continuously source drug-development pipelines in Korea and abroad and rapidly co-develop or license them out to global pharmaceutical companies (Alphasquare reproduction of the business summary; Simply Wall St). The registry-based business description (Saramin) lists: - electronic components: high-frequency coils, transformers and SMD inductors; - equipment for manufacturing semiconductors and flat-panel displays. The KRX industry code is electronic coils, transformers and other electronic inductor manufacturing. The articles of incorporation list 85 business purposes, headed by "manufacture and sale of exposure equipment (노광기) for PCB, LCD and PDP" (TheVC). At its December 2015 IPO, the company (then CEO Lee Woo-suk) described its core products as follows (Edaily IPO interview, Dec-2015): - front-end semiconductor equipment for cleaning, photoresist coating and developing; - back-end bonding (adhesion) equipment; - FPD HP/CP equipment for drying glass. It claimed the ability to support 7 of 20 semiconductor process steps once its etch, characterization-test and final-test tools under development were included. It also said it had secured capacity of about 1.5x its then-current revenue to serve Samsung's Pyeongtaek fab and Chinese panel makers (BOE, Tianma). ### Independent characterisation | Engine | What it does | Evidence of scale | Assessment | |---|---|---|---| | Semiconductor & display equipment | Wet/track-type equipment (cleaning, coat/develop), bonding equipment, HP/CP thermal units, exposure equipment | "Semiconductor [products]" = 40.09% of FY2025 revenue (≈KRW 10.1 bn); "Display [products]" = 0.09% | Legacy core; customer concentration on Samsung Electronics / Samsung Display (Aju News, Sep-2026) | | Electronic components | High-frequency coils, transformers, SMD inductors (ex-Daeshin Electronics, now the Gumi branch; Tianjin subsidiary) | Included in "Other [products etc.]" = 59.83% of FY2025 revenue (≈KRW 15.1 bn, shared with other lines) | Low-margin commodity magnetics; accounts for the post-2024 revenue uplift | | Bio / healthcare | PharmaWorks (100%) and Cellforium (70%). Therapeutic programs reportedly target Zika/MERS, glaucoma, non-alcoholic fatty liver disease, chronic kidney disease, and immunotherapy for cancer/inflammatory disease | No disclosed revenue; Simply Wall St business description | Option value only; bio plant and acquisitions delayed for lack of funding (IB Tomato, Apr-2026) | | Real-estate development vehicles | Road One Real Estate Fund No.1 PEF (99.49%), Marine One Development (consolidated via CB holdings), E&K Consortium (99.96%), Kingdom Fore | KRW 39.5 bn of development land (용지) in inventory at FY2025 and June 2026 (Valueline) | The largest single asset class on the balance sheet; illiquid; linked by press reports to the former Sambu Construction chairman's family | THE CODI today is a holding-style conglomerate of small, loss-making businesses wrapped around a legacy Samsung equipment supplier. Four economic engines can be identified: **Business model / revenue model.** Revenue is almost entirely product sales (equipment and components). No subscription, licensing or recurring-service revenue is disclosed. Equipment revenue is project-based and recognised around customer acceptance (검수). Press coverage notes that revenue swings with customer capex timing and acceptance dates (JobPost, Oct-2026). Equipment is sold to semiconductor and display fabs. Components are sold to electronics/power-supply OEMs (customer names for components are not disclosed). **Value-chain position.** THE CODI is a tier-2/tier-3 domestic tool supplier. It supplies peripheral process modules (thermal plates, wet-process and bonding stations) rather than critical lithography/etch/deposition tools. It is a price-taker to Samsung and relies on Samsung's line investment cycles (Pyeongtaek, Godeok, Onyang, Xi'an were cited at IPO). **End-markets.** Memory and foundry semiconductor fabs; OLED/LCD display fabs; general electronics (coils/transformers); and prospectively biopharma and, if the pending control change completes, robotics/AI.

Revenue$0.0B
Employees30
Market CapN/A
Founded1999
Cheonan, South Korea
CoAsia

CoAsia Corporation

Premium
Information Technology

CoAsia Corp. is a Korean small-cap holding-and-operating company that is partway through changing what it is. Historically it was an assembler of IT components: microspeakers (BSE), camera modules and lenses, and LED packages, all tied to the Samsung Galaxy supply chain. Since 2019 it has moved its centre of gravity toward system-semiconductor design services. This runs through CoAsia SEMI, a 73%-owned Samsung Foundry SAFE™ Design Solution Partner (DSP) offering RTL-to-silicon custom ASIC "turnkey" work, 2.5D/3D advanced packaging and chiplet integration for AI/HPC customers such as Tenstorrent and Rebellions. The legacy components arm is now consolidated mainly through KOSDAQ-listed CoAsia CM (lenses and camera modules for Samsung smartphones; new ToF/robotics optics) and the Itswell LED business. It remains the cash-generating but thin-margin majority of revenue. The investment case depends on whether the semiconductor arm's rapid revenue growth turns into durable mass-production profits before the group's leveraged, loss-making balance sheet forces further dilution. --- **What the company does.** CoAsia Corp. is the listed parent of the "CoAsia Group" in Korea. The group's website lists these affiliates: CoAsia SEMI, CoAsia CM, CoAsia Nexell, Itswell, Re-Investment (리인베스트먼트), and the Taiwan-based CoAsia Electronics [S12]. CoAsia Electronics is a related party and is not shown in the sources as a consolidated subsidiary. Consolidated revenue falls into two reported business lines. As of Q2 2026, "electronic components manufacturing" was about 59% of revenue and "non-memory system semiconductor services" about 40% [S4]. **Company's own description.** The corporate site describes CoAsia as a global technology company. It says the company provides design-to-manufacturing solutions across system semiconductors, AI, optics and camera modules, and LEDs [S12]. Morningstar's vendor description is older. It lists distribution-type product lines (mobile, memory, display and CMOS image solutions, audio codecs, camera and fingerprint modules) [S54]. These reflect the group's historical Samsung component distribution heritage and should be treated as possibly outdated. **Independent characterisation.** In practice the economics divide into three engines: 1. **Custom silicon services (CoAsia SEMI).** This is a dedicated Samsung Foundry DSP. It turns fabless customers' RTL into physical layouts suited to Samsung processes. It also offers full "custom ASIC turnkey" services: wafer procurement as Samsung's authorised wafer agent, packaging and test [S12][S33]. Revenue comes from non-recurring engineering (NRE), recognised on a percentage-of-completion basis [S34], plus turnkey mass-production wafer and chip supply. CoAsia SEMI's revenue reached KRW 90.2bn in H1 2026, against KRW 60.8bn for all of FY2025 [S12]. 2. **Optical and camera components (CoAsia CM, ex-Diostech / CoAsia Optics).** CoAsia CM makes smartphone camera lenses and compact camera modules. Samsung Electronics' Galaxy S and A series are the anchor customer [S42]. In FY2025 it had revenue of KRW 258.2bn and operating profit of KRW 5.3bn [S47]. It is diversifying into ToF 3D-sensing and robot vision modules [S44]. 3. **LED packages (Itswell).** Itswell makes automotive interior and "communication-type" LEDs. Examples are its ISELED membership and LEDs for the Hyundai Ioniq 5 [S40]. In November 2025, a wafer licence with Inova let CoAsia SEMI fabricate ISELED driver chips, so the ISELED value chain is now vertically integrated from wafer to module [S18]. **Revenue model mix.** The company does not disclose a product/service/licensing breakdown. By the analyst's characterisation, about 60% of revenue is manufactured products (lenses, modules, LEDs) and about 40% is services and turnkey semiconductor supply. Turnkey supply mixes NRE service fees with pass-through wafer and chip product revenue. Licensing and subscription revenue is immaterial or n/d. **Value-chain position.** CoAsia SEMI sits between fabless chip designers and Samsung Foundry/OSATs. This is the role GUC plays for TSMC, and CoAsia has said openly that it is copying that model [S36]. CoAsia CM is a Tier-1 component supplier to Samsung MX. Itswell is a component supplier to automotive lamp and module makers. **Customer types and end-markets.** The customers are AI accelerator start-ups and hyperscale-adjacent chip developers (Tenstorrent, Rebellions) [S14][S15], consumer-electronics OEMs (LG Electronics, through a national R&D programme) [S16], and Samsung Electronics' smartphone division [S42]. Automotive OEMs are served indirectly (Hyundai/Kia via ISELED) [S18], and robotics and humanoid makers are a new market [S45].

Revenue$0.3B
Employees82
Market CapN/A
Founded1993
Incheon, South Korea
Cmb.Tech

Cmb.Tech N.V.

Premium
Information Technology

CMB.TECH is one of the largest listed, diversified maritime groups globally, with about 235 vessels across five operating divisions: **Bocimar:** dry bulk **Euronav:** crude tankers **Delphis:** containers **Bochem:** chemical tankers **Windcat:** offshore energy and port vessels The group is controlled by Belgium's Saverys family and led by CEO Alexander Saverys. Since 2023 it has turned a pure-play VLCC/Suezmax owner into a multi-segment platform. The steps were the sale of 24 VLCCs to Frontline, the absorption of the Saverys-owned CMB.TECH, and the stock-for-stock takeover of Golden Ocean. Its distinctive claim is "future-proof" tonnage. The fleet is young (Newcastlemax average age 3.2 years) and increasingly ammonia- or hydrogen-capable. It is anchored by long-term charters with industrial counterparties such as Fortescue and MOL, and complemented by hydrogen and ammonia fuel supply. Financially the group is a high-operating-leverage spot earner with about 80% of 2026 shipping days exposed to spot. It recycles older ships into newbuilds through repeated asset sales at large gains. Net debt of about USD 5.3 bn makes it one of the more levered large-cap shipping equities. --- ### Company self-description The company's standard description has three parts: - It calls itself one of the largest listed, diversified and future-proof maritime groups worldwide. - It lists the fleet as dry bulk vessels, crude oil tankers, chemical tankers, container vessels, offshore energy vessels and port vessels. - It adds that it supplies hydrogen and ammonia fuel through its own production or third-party producers, from an Antwerp headquarters with offices across Europe, Asia and Africa. ### Independent characterisation CMB.TECH is best understood as a capital-intensive vessel-owning and chartering platform. Revenue is overwhelmingly freight and hire income. It is not a technology or fuel company, despite the name. Four characteristics matter for analysis. 1. **Earnings engine.** Most revenue comes from voyage charters (spot) in dry bulk and crude tankers, recognised load-to-discharge under IFRS 15. Management stated on the Q1 2026 call that the company has about 53,000 shipping days in 2026, of which about 80% are spot. This produces very high sensitivity to Capesize and VLCC/Suezmax rates. 2. **Contracted ballast.** A contract backlog of USD 3.26 bn (Q1 and Q2 2026) provides fixed cash flows. Its main components are: - Long-term time charters in containers (10–15-year charters) - Chemical tankers (7- and 10-year charters) - CSOVs (multi-year charters) - FSOs - Selected VLCC, Suezmax and Newcastlemax time charters with industrials 3. **Asset-rotation profits.** A recurring and material share of reported profit is capital gains on vessel sales: - FY2024: USD 635.0 m - FY2025: USD 192.6 m - H1 2026: USD 394.9 m - Q3 and Q4 2026 (announced): about USD 231 m Sales proceeds fund the newbuilding programme. Investors must separate "underlying" from "reported" earnings. 4. **Decarbonisation optionality.** Several dual-fuel ammonia/hydrogen newbuilds and charters (Fortescue, MOL) create a niche franchise with industrial charterers seeking lower-emission freight. This adds contract stickiness and future regulatory positioning, at the cost of higher upfront capex. ### Revenue model mix | Revenue type | Description | Indicative share | |---|---|---| | Voyage charter (spot) revenue | Dry bulk (Newcastlemax, Capesize, Kamsarmax/Panamax) and crude tankers (VLCC, Suezmax); chemical tankers in the Stolt pool | Majority (about 80% of 2026 shipping days are spot per management; revenue share not disclosed) | | Time charter revenue | Containers, chemical tankers, CSOVs, CTVs, FSOs, selected tankers and bulkers | Minority; backs the USD 3.26 bn backlog | | Pool/other operating income | Pool management, other operating income (USD 29.8 m FY2025; USD 37.1 m H1 2026) | Small | | Fuel supply (hydrogen/ammonia) | Hydrogen production and supply (e.g., Namibia, Antwerp) and ammonia supply-chain investments (China) | Immaterial to group revenue; not separately disclosed | | Product/licensing/subscription | None material | 0 | ### Value-chain position and customers CMB.TECH sits in the asset-owning and chartering layer of maritime logistics: **Upstream:** are shipyards (notably Chinese yards for newbuildings), engine makers and fuel suppliers. **Downstream:** are cargo owners and charterers: - Dry bulk: iron ore miners (e.g., Fortescue), coal and bauxite shippers, grain traders, steelmakers - Crude: oil majors, national oil companies and traders - Containers: liner operators - Chemicals: chemical producers via the Stolt pool and time charterers (MOL Chemical Tankers) - Offshore wind: developers and turbine OEMs (CSOV/CTV) ### End-markets served 1. Seaborne iron ore, coal, bauxite and grain (dry bulk) 2. Seaborne crude oil (VLCC/Suezmax), plus offshore storage (FSO) 3. Container liner tonnage (charter-out of 6,000 TEU and 1,400 TEU vessels) 4. Chemical and specialty liquids (25k dwt stainless-steel tankers) 5. Offshore wind construction and operations & maintenance (CSOV, CTV, MPASV), plus port services (hydrogen-powered tugs and utility vessels) 6. Low-carbon marine fuels (hydrogen, ammonia)

Revenue$1.7B
Employees2,240
Market Cap$5.8B
FoundedN/A
Antwerp, Belgium
Clinomics

Clinomics Inc.

Premium
Information Technology

Celestra Inc., known until 2025 as Clinomics, was founded in 2011 as a liquid-biopsy and cancer-genomics company. In 2018 it merged with Zeromics, the genome-analysis company of UNIST professor Park Jong-hwa. It was the first UNIST faculty start-up to list on KOSDAQ, through the growth-potential special-listing track in December 2020. Its stated platform combined multi-omics genome analysis, an in-house device for isolating circulating tumour cells and cell-free DNA, and consumer and clinical genetic tests. COVID-19 testing, mainly through its US subsidiary, drove a one-off peak in FY2021 of KRW 55.4bn revenue and KRW 22.9bn operating profit. After demand collapsed, the company recorded large losses. Control passed to a new investor group in 2024, and the company moved into a hotel, a mushroom smart farm and health supplements. By 2025–2026 it had received two audit disclaimers, entered and then exited court rehabilitation, and was facing delisting. Its core diagnostics business has effectively stopped operating. --- ### Company's own characterisation The company's latest annual report (FY2025 business report) could not be retrieved directly. The most recent company-sourced business descriptions, as summarised by data vendors, are: **Core description (GuruFocus / Morningstar profiles):** a biotechnology company offering genome-based early diagnosis of cancer and other diseases, which aims to address ageing and disease through liquid biopsy and multi-omics technology. **Business lines (EMIS profile, based on 2023 data):** two main businesses. - A multi-omics service business that predicts physical traits and disease risk from genome tests and offers multi-omics-based early detection of major diseases such as cancer. - A liquid-biopsy cancer diagnosis and screening business that sells devices for isolating blood cells and DNA, along with diagnostic and monitoring kits for cancer mutations. It is also developing blood-based early cancer detection products. **Main products listed in IR disclosures (IRGO):** Geno Series, CD-PRIME, Cancer Prime. **2025-era description (TheVC):** NGS-based contract research services under B2B and B2C models, with revenue diversification through health functional foods and a hotel business. ### Independent characterisation From IPO to 2023, Clinomics was a small Korean clinical-genomics and liquid-biopsy services company. Its business model mixed three things: 1. **Fee-for-service testing:** consumer DTC genetic tests, clinical cancer panels and research sequencing. 2. **Device and kit sales:** liquid-biopsy sample-preparation devices and cancer-mutation kits. 3. **Pandemic testing:** COVID-19 diagnostic kits and lab testing, mainly through Clinomics USA in 2020–2022. The COVID business masked the fact that the core genomics products never reached commercial scale (Bizwatch, Nov 2025). After the change of control in 2024, the company became a loosely connected holding of unrelated assets: a Seoul hotel, a 40% stake in a mushroom smart farm (Gageum Nongsan), and a health-supplement subsidiary (CoNF). The financial press reported that these acquisitions were made partly to stay above the KOSDAQ revenue threshold that triggers "administrative issue" designation (Financial News, Jul 2025; The Tracker, Sep 2025). By 2026, operating activity was minimal. Standalone Q1 2026 revenue was about KRW 24 million. In the H1 2026 report, the company confirmed that Q2 revenue was below KRW 300 million and H1 revenue below KRW 700 million, and that its equity was fully impaired. ### Revenue model mix | Revenue type | Description | Approx. weight | |---|---|---| | Testing services (product-like service fees) | Genome, DTC and cancer tests; COVID-19 testing (historic) | Dominant in FY2020–FY2022. Exact split not publicly disclosed. | | Product sales | Liquid-biopsy devices, diagnostic kits, COVID kits, health functional foods | Not publicly disclosed | | Research services | NGS-based contract research | Not publicly disclosed | | Hospitality | New Oriental Hotel (acquired 2024) | Not publicly disclosed. The hotel was reported as not operating at acquisition. | | Subscription / licensing | Genpic app (an affiliate's app, not consolidated revenue); distribution of Singlera tests | Not publicly disclosed | ### Value-chain position, customers and end-markets **Value chain:** a mid-stream analysis-service provider. It sourced sequencing platforms from third parties and licensed some tests (Singlera's), while running its own lab analysis, bioinformatics and reporting. Its in-house sample-preparation device for CTC and ctDNA isolation was the main upstream differentiator. **Customers:** hospitals and clinics (cancer panels), consumers (DTC tests under Korea's limited DTC regime), research institutions (sequencing services), government (it carried out national R&D projects, including 2023 work on infectious diseases and epidemiological and mathematical modelling, per TheVC), and in 2020–2022 COVID-testing clients in the US. **End-markets:** precision oncology and liquid biopsy, consumer genomics and wellness, infectious-disease diagnostics, and from 2024 hospitality and agri-food.

Revenue$0.0B
Employees78
Market CapN/A
Founded2011
Ulsan, South Korea
Clicks

Clicks Group Limited

Premium
Information Technology

Clicks Group is South Africa's dominant retail-led healthcare platform. It combines the country's largest retail pharmacy chain (Clicks: 999 stores and 797 dispensaries at February 2026) with its leading full-range pharmaceutical wholesaler, United Pharmaceutical Distributors (UPD). The model is vertically integrated. Clicks buys about 98% of its pharmaceutical needs from UPD. UPD in turn supplies private hospital groups and independent pharmacies, and provides pre-wholesale "bulk" distribution for drug manufacturers. Front-shop health, beauty and personal care categories, where Clicks holds leading NielsenIQ shares (43.1% in skincare), are monetised through a 12.9-million-member ClubCard programme that drives about 84% of sales. Growing private label adds further margin, at 26.5% of sales. The group has historically delivered 40–50% returns on equity with no interest-bearing debt. That record earned it a long-standing premium valuation. In 2026 the stock de-rated sharply as earnings growth slowed to a guided 4–9%, rivals (Dis-Chem and Shoprite's Medirite) intensified their offers, and a warehouse-system disruption exposed execution risk. --- ### Company's own description (paraphrased from the FY2025 results and integrated report, S1/S6) The group describes itself as a leader in healthcare. It frames its purpose around widening access to affordable healthcare for South Africans. It presents Clicks as the country's leading health, wellness and beauty retailer and its foremost pharmacy chain: an expanding network of over 990 stores and 780 pharmacies at FY2025 year-end, supported by a growing digital presence. It presents UPD as the country's leading full-range pharmaceutical wholesaler, which provides the distribution capability for the group's healthcare strategy. The 2025 sustainability report adds that the group runs "vertically integrated operations". Its brand portfolio includes exclusive franchises (The Body Shop), owned brands (Sorbet) and private labels (for example MyEarth). ### Independent characterisation Clicks Group is best understood as three interlocking economic engines. 1. **A high-frequency convenience health and beauty retailer (Clicks front shop).** This engine earns most group profit. Front-shop health, beauty and personal care, and general merchandise (including small electrical appliances) together made up about 73% of FY2025 retail turnover. Margins come from private label, exclusive brands, promotional intensity (47.8% of turnover sold on promotion in H1 FY2026) and supplier-funded "other income" (advertising and cost recoveries). Retail other income rose 17% to R2.20bn in FY2025. 2. **A regulated retail pharmacy chain.** Dispensary sales were R10.06bn (26.8% of retail turnover excluding Unicorn) in FY2025. Medicine prices are regulated through the Single Exit Price (SEP) and a capped dispensing fee. This means pharmacy is a footfall and loyalty driver rather than a high-margin line. The binding growth constraint is the Department of Health's licensing of new dispensaries. In H1 FY2026, 105 stores still had no dispensary. 3. **A pharmaceutical wholesaler and logistics provider (UPD).** UPD earned R18.7bn of FY2025 segment turnover at a 3.3% trading margin. It also manages notional turnover for bulk-distribution clients that is not booked as revenue: total managed turnover was R30.5bn in FY2025. UPD gives Clicks supply security and purchasing scale, and earns fees from manufacturers. ### Revenue model and mix **Product sales:** (goods sold to customers): R47.83bn turnover in FY2025, which is 93% of IFRS revenue of R51.43bn. **Service and fee income:** (booked as "other income"): R3.46bn in FY2025. This comprises distribution and logistics fees of R1.45bn (UPD bulk and agency services) and cost recoveries and other income of R2.01bn (supplier advertising, promotional recoveries, Sorbet franchise fees and similar). **Franchise and licensing income:** Sorbet franchise fees from about 190 franchised salons (amount not separately disclosed). The Body Shop is operated *under* licence, so it is a cost to Clicks rather than income. **Subscription or SaaS:** the LEAP pharmacy management system (developed by 180 Degrees) is being marketed to third-party pharmacies. Revenue is not separately disclosed. ### Value-chain position, customers and end-markets **Upstream:** Clicks sources from multinational and local fast-moving consumer goods and pharmaceutical manufacturers and from private-label contract manufacturers. Since the August 2024 Unicorn disposal it has had no pharmaceutical manufacturing. **Midstream:** UPD's five owned distribution centres plus three Clicks retail distribution centres. The group reports that the Clicks distribution centres supply about 98.5% of the chain's product needs (S14 history page). **Downstream customers:** mass and middle-income consumers (247–252 stores sit in low-income areas and contribute about 23.4–23.7% of retail turnover); medical-scheme and cash pharmacy patients; private hospital groups (36.2% of UPD fine-wholesale turnover in FY2025); about 1,020 independent pharmacies; and pharmaceutical principals (bulk distribution). **End-markets:** South African retail pharmacy, front-shop health and OTC, beauty and personal care, baby, small electrical appliances, private-hospital pharmaceutical supply and pharma logistics. Cross-border operations cover Namibia, Botswana, Eswatini and Lesotho. ### Operating KPIs (five-year) | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Total retail stores (number) | 841 | 898 | 950 | 1002 | 1060 | | Clicks stores (number) | 781 | 837 | 881 | 930 | 985 | | In-store pharmacies (number) | 621 | 673 | 711 | 720 | 780 | | The Body Shop standalone stores (number) | 59 | 58 | 61 | 57 | 55 | | Clicks Baby standalone stores (number) | 1 | 3 | 4 | 6 | 6 | | Sorbet corporate stores (number) | 0 | 0 | 4 | 9 | 14 | | Weighted retail trading area (thousand m2) | 384.8 | 397.1 | 425.4 | 448.3 | 474.5 | | Weighted annual sales per m2 (ZAR) | 68934 | 72822 | 73200 | 77666 | 78432 | | Permanent employees (number) | 15871 | 16492 | 18447 | 19621 | 20102 | | Metric | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---| | ClubCard active members (millions) | 9.7 | 10.4 | 11.8 | 12.6 | | ClubCard cashback paid (ZAR m) | 601 | 689 | 780 | 855 | | In-store clinics (number) | 199 | 203 | 206 | 225 | *Sources: S1 (FY2024–FY2025), S3 (FY2022–FY2023), S4 (FY2021–FY2022). FY2021 sales per m2 is for continuing operations. FY2025 Clicks stores include 1 UniCare store.* *Sources: S4, S3, S13/S6 (FY2024), S1/S6 (FY2025). At H1 FY2026: 12.9m members, 83.7% of sales, R527m cashback in six months, 226 clinics.*

Revenue$2.7B
Employees20,682
Market CapN/A
Founded1968
Cape Town, South Africa
CLASSYS

CLASSYS Inc.

Premium
Information Technology

CLASSYS is South Korea's largest listed energy-based aesthetic device (EBD) company by market capitalisation and profitability. It runs a "razor-and-blade" model: it installs high-intensity focused ultrasound (HIFU), monopolar radiofrequency (RF), microneedle RF (MNRF) and laser platforms in clinics, then sells high-margin, procedure-linked cartridges and tips. Its flagship HIFU franchise, Shurink, sold abroad as Ultraformer, and its monopolar RF system Volnewmer, sold in the US as Everesse, have built an installed base of more than 48,000 cumulative units since founding (IR Book 2Q26). The company has posted operating margins near 50% for five consecutive years. Bain Capital has controlled it since 2022. Since then it has merged with Ilooda (October 2024) to add MNRF and lasers, bought its Brazilian distributor MedSystems (2025–26), and begun moving to direct sales in Japan and Latin America. It now faces a margin reset from direct-distribution costs, a slowing Korean market, a cut to 2026 guidance, a stock down more than 60% from its high, and an unresolved private-equity exit. --- ### What the company does CLASSYS designs, manufactures and sells non-invasive and minimally invasive aesthetic medical devices, together with their consumables, to dermatology and plastic-surgery clinics and aesthetic practices. It also sells home-use beauty devices and cosmetics. After merging with Ilooda in October 2024, management describes the portfolio as covering the four main EBD technology classes: HIFU, monopolar RF, MNRF and lasers (Source: Classys merger completion release, Metro Seoul / Medigate News, 2–4 Oct 2024). The company's 2Q26 disclosure says it sells in more than 80 countries, though press releases in 2025 cited 60–70. The difference reflects partner coverage versus active markets (Source: Quartr summary of 1H26 half-year report; Wanted company profile; Wikipedia). ### Business and revenue model | Revenue stream (FY2025, KRW bn) | Amount | % of revenue | Nature | |---|---|---|---| | Devices | 174.0 | 51.7 | Capital equipment, one-off | | Consumables | 154.6 | 45.9 | Recurring, procedure-linked | | Homecare (B2C devices) | 7.3 | 2.2 | Consumer product | | Rentals (Korea) | 0.9 | 0.3 | Device leasing | | Total | 336.8 | 100.0 | — | The model is an installed-base platform. A device sale carries a one-off margin and establishes the clinic relationship. Each procedure then consumes a proprietary cartridge (HIFU) or tip (RF/MNRF), which produces recurring revenue. Management has said gross margin approaches 80% when the consumables mix exceeds 50% (Source: Hankyung, 8 May 2024, 1Q24 results commentary). Source: IR Book 4Q25, "Sales by Brand" table, FY2025. Percentages are derived. There is no meaningful subscription or licensing revenue. From 2Q26 the company also books commission revenue in Japan as it moves to direct sales there (Source: IR Book 2Q26, gross-profit commentary). ### Value-chain position Historically CLASSYS was a designer-manufacturer that exported through exclusive national distributors, such as MedSystems in Brazil, Cartessa Aesthetics in the US and partners in Thailand. It is now integrating forward into distribution: **Brazil, Colombia, Argentina:** acquired the MedSystems group (77.5% of JL Health plus 100% of the Colombian and Argentine distributors). The deal was agreed in October 2025 and consolidated from March 2026. **Japan:** Classys Japan was established in 2024. Management targets a 100% transition to direct sales (IR Book 2Q26, 2H26 initiatives). **Korea:** sells direct to clinics. **US and Europe:** distributor-led. Cartessa handles the US. ### Customers and end-markets Customers are dermatology clinics, plastic-surgery clinics, aesthetic chains and medspas. In Brazil they include more than 15,000 hospitals and aesthetic spas served by MedSystems (MedSystems IR Book, Oct 2025). Retail and e-commerce consumers buy the homecare line. The end market is non-surgical lifting, tightening, skin rejuvenation and vascular/pigment treatment. Demand comes from consumer spending on "well-aging" procedures, medical tourism (inbound tourism to Korea is cited as a consumables driver by LS Securities, June 2025) and the global shift toward minimally invasive procedures. ### Company's self-description and independent characterisation The company describes itself as a global medical aesthetics platform with end-to-end EBD solutions. It claims to be the only company able to offer personalised, combined-procedure experiences across all major energy modalities (paraphrasing CEO Yoon Jun-oh, Asia Economy, 12 Oct 2026). It sets a target of US$1 billion in revenue by 2030 (IR materials; Edaily, Oct 2026). **Independent characterisation:** CLASSYS is a highly cash-generative, mid-sized device company. Its economics resemble a consumables franchise: gross margin 77–79% and EBITDA margin 53–55% in FY2024–25. That profile is now being diluted on purpose by vertical integration into lower-margin distribution (MedSystems EBITDA margin in the low teens; BizWatch, Jan 2026) and by heavier spending on marketing, R&D and senior hires. The strategic question is whether direct control of channels in Latin America and Japan, plus entry into the US and China, can sustain the 30–40% growth that historically justified premium multiples. The stock's de-rating in 2026 shows the market doubts it.

Revenue$0.2B
Employees537
Market CapN/A
Founded2007
Seoul, South Korea
CJFreshway

CJ Freshway Corporation

Premium
Information Technology

CJ Freshway is South Korea's largest B2B food-ingredient distributor and one of the four large contract-catering operators, sitting inside the CJ Group consumer-food ecosystem alongside CJ CheilJedang, CJ Foodville and CJ Logistics. It generated record consolidated revenue of KRW 3,481.1bn and its first-ever operating profit above KRW 100bn (KRW 101.7bn) in FY2025, yet still earns a thin ~2.9% operating margin characteristic of distribution-heavy models. Roughly three-quarters of revenue comes from moving ingredients — to franchise chains, independent restaurants, food manufacturers, schools, childcare centres, nursing homes and caterers — through a 16-site national cold-chain network; the remainder comes from operating cafeterias, hospital kitchens and airport/leisure concessions. Management is attempting to re-rate the business from an offline wholesaler into an "O2O" platform operator (via majority control of B2B marketplace Sikbom since March 2026) and a "kitchenless" catering provider, while carrying a regulatory overhang from a KRW 24.5bn Fair Trade Commission penalty now before the Supreme Court. --- ### What the company does CJ Freshway's operations reduce to two economic engines: 1. **Food-ingredient distribution (식자재 유통)** — sourcing, storing and delivering agricultural, livestock, seafood, processed-food and kitchen-consumable products to commercial kitchens. Channels include national restaurant franchise chains, independent restaurants (direct), food-ingredient marts and regional agents, CJ Group affiliates and third-party food manufacturers (raw-material supply), online platforms, and institutional kitchens (childcare, schools, elderly-care, caterers, military). 2. **Foodservice / contract catering (단체급식·푸드서비스)** — operating employee cafeterias (industrial sites and offices), hospital food services, school and university kitchens, highway rest-area, airport, resort, golf-course and water-park concessions, grab-and-go "Snack Pick" corners, and mobile/kitchenless meal delivery ("Freshmeal On") to sites without kitchens (seniors' facilities, apartment complexes). A small manufacturing arm (subsidiary Freshplus, plus a central kitchen) produces sauces, dressings, seasonings, pre-processed produce and B2B convenience meals mainly for internal use and for franchise customers. ### The company's own description (paraphrased from IR materials and annual-report summaries) The company describes itself as Korea's representative food-ingredient distribution and food-service company whose mission is to be a "food business partner" — supplying everything a commercial kitchen needs (agricultural, marine, livestock and processed products, plus consumables) and layering value-added services (menu development, recipe training, hygiene education, business consulting, customised products) on top. Since late 2024, management has organised reporting around (a) a Distribution business (restaurant ingredients + food raw materials) pursuing an O2O model, and (b) a Foodservice business (institutional-meal ingredients + contract catering) pursuing a kitchenless model (CJ Freshway 2Q25 IR presentation; Q1 2025 press release). ### Revenue model | Revenue type | Description | Approx. weight | |---|---|---| | Product sales (merchandise distribution) | Gross-basis resale of ingredients; margin from purchasing scale, PB mix, logistics density | ~75% of FY2025 revenue (food-material distribution, net of eliminations) | | Service revenue (contract catering, concessions) | Per-meal or management-fee contracts; concession revenue at airports/leisure sites | ~24% of FY2025 revenue (food service) | | Manufacturing & other | Sauces, pre-processed produce, rental income | ~0.7% (FY2025, net) | | Platform / marketplace (Sikbom) | Commission and service revenue from a B2B open-market platform consolidated from 31 March 2026 | Small; included in online revenue (~KRW 52.1bn in 2Q26) | | Subscription / licensing | No material subscription or licensing revenue disclosed | Not publicly disclosed | Note: In FY2025 approximately 99.9% of revenue (KRW 3,478.7bn) was generated in Korea (The Fact, 31 March 2026, citing the FY2025 annual report). ### Value-chain position **Upstream:** Domestic farm sourcing (contract cultivation), livestock and seafood procurement, global sourcing (historically via China, Vietnam and US subsidiaries — e.g., canned tuna, frozen shrimp, sweetcorn), exclusive/brand partnerships (e.g., Haidilao sauces B2B, Bebecook infant food, NH Nonghyup premium livestock). **Midstream:** Processing (Freshplus Gongju plant, Eumseong sauce plant opened November 2024, central kitchen), quality assurance (Food Safety Center since 2003), and a national cold-chain logistics network (7 wide-area centres among 16 total), supplemented by CJ Logistics. **Downstream:** B2B customers across restaurant, institutional and manufacturing channels, plus direct-to-diner contract catering. CJ Freshway is therefore a vertically integrated midstream intermediary with partial upstream (processing) and partial downstream (catering) integration. ### Customer types and end-markets | End-market | Customer examples / channels | Brands / formats | |---|---|---| | Restaurant franchise chains | Large franchisors (e.g., No More Pizza — KRW 72bn/yr contract, Oct 2024; Sekwang Green Food — KRW 60bn contract, Jun 2026) | Franchise-specific R&D products; sauce development | | Independent restaurants | Direct delivery; Sikbom marketplace | Itswell PB; Sikbom; (Freshen app closed 29 Sep 2026) | | Wholesale / marts / agents | Food-ingredient marts, regional agents | CJ CheilJedang and Freshway PB/NB | | Food manufacturers | CJ Group affiliates, external processors | Food raw materials (dairy, seafood, etc.) | | Childcare & kindergartens | Daycare kitchens | Ainuri (아이누리) | | Schools | School kitchens | Teunteun School (튼튼스쿨) | | Elderly care / welfare | Nursing homes, mobile meal providers | Healthy Nuri (헬씨누리) | | Caterers & military | Catering firms; military units (direct/indirect) | Meal-solution products | | Industrial & office cafeterias | Large corporates | Greenteria (premium cafeteria), Snack Pick | | Hospitals | Patient & staff meals | Hospital-HACCP-certified kitchens | | Concession / leisure | Incheon Airport food court, Haengdamdo rest area, golf courses, water parks | Concession formats | | Apartments / seniors (kitchenless) | Apartment breakfast/lunch, seniors' facilities | Freshmeal On (프레시밀온) | ### Independent characterisation CJ Freshway is best understood as a scale-driven, low-margin, working-capital-light (negative working capital) distributor that is trying to buy its way into a platform economics story. Its structural strengths are logistics density, purchasing scale and CJ Group product access; its structural weakness is that, unlike Samsung Welstory, Hyundai Green Food or Ourhome, it has comparatively little captive (affiliate) catering volume, so its mix is skewed toward lower-margin distribution (Dealsite, 10 Nov 2025, citing a company official). The 2025–2026 strategy — merging Freshone, taking control of Marketboro (Sikbom), closing the in-house Freshen app, and scaling kitchenless catering — is essentially a bet that (i) online penetration of B2B ingredients (~4% today per Kiwoom estimates) will rise sharply and (ii) labour scarcity will push institutional clients toward centrally produced, kitchen-free meal solutions. Near-term, these bets are dilutive to margins (2Q26 operating profit −14.2% YoY on online investment).

Revenue$2.4B
Employees8,225
Market CapN/A
Founded1988
Yongin, South Korea
CJ

CJ Cheiljedang Corporation

Premium
Information Technology

CJ CheilJedang is South Korea's largest food company. It is the flagship operating unit of CJ Group, and through a 40.16% stake it consolidates CJ Logistics, Korea's largest logistics company. Its core is a branded processed-food franchise built around bibigo, Hetbahn, Beksul and Dasida. Since the 2019 acquisition of US frozen-food maker Schwan's, that franchise has become a global K-food platform. In FY2025 overseas food sales (KRW 5.92tn) exceeded domestic food sales for the first time. The second pillar is a scale biotechnology business: fermentation-derived amino acids (lysine, tryptophan, valine, arginine and others), nucleotides and specialty ingredients. The company has historically been the world's largest amino acid producer. The company is now in its most significant restructuring since the 2007 spin-off. It divested CJ Feed&Care, abandoned a planned sale of the bio business, and on 1 July 2026 reorganized into three divisions (Lifestyle Food, Technology Materials, Core Materials). It is also contending with record antitrust fines, compressed bio margins and elevated leverage. --- ### What the company does CJ CheilJedang operates three business families, plus one consolidated subsidiary group: 1. **Food (now "Lifestyle Food")** - Branded processed foods: frozen dumplings (mandu), instant/processed rice, kimchi, seaweed snacks, sauces and pastes, chicken, frozen pizza, desserts, Asian appetizers, and beverages including fruit vinegar. - Domestic "food ingredients" businesses: sugar, flour, edible oils, starch sweeteners and premixes. Under the July 2026 reorganization these sit in Core Materials. - Operates globally. North America runs through CJ Foods America / CJ Schwan's, and there are platforms in Japan, China, Vietnam, Europe and Oceania. 2. **Bio (now split into "Technology Materials" and "Core Materials")** - Fermentation-based "green bio" products. - Feed-grade amino acids: lysine, threonine, tryptophan, methionine, valine, arginine, isoleucine, histidine. - Food-grade flavour enhancers: nucleotides (IMP/GMP) and the natural seasoning material TasteNrich. - New materials: PHA biodegradable plastic and allulose. - Per Korean press (KED, Feb 2025), amino acids account for about 90% of bio sales. 3. **Red bio / health (non-core, small)** - CJ Bioscience (microbiome therapeutics, launched January 2022). - Batavia Biosciences (Dutch cell and gene therapy CDMO; 75.8% stake acquired in 2021). - CJ Wellcare (health functional foods). 4. **CJ Logistics (consolidated, 40.16% owned)** - Korea's largest parcel, contract logistics and global forwarding company. - By revenue it is the largest consolidated segment: about 43% of Q2 2026 consolidated sales, versus 39% food and 18% bio (Butler.works segment split). ### Business and revenue model | Dimension | Characterization | |---|---| | Product vs. service mix | Predominantly product sales (processed foods, food ingredients, amino acids). Service revenue comes almost entirely from CJ Logistics. Subscription and licensing revenue is immaterial, although the company licensed lysine strain technology to a Chinese producer in February 2026 (CJ newsroom) | | Value-chain position | Vertically integrated from commodity processing (raw sugar, wheat, corn, soybean) through fermentation and food manufacturing to branded consumer goods. Logistics adds downstream distribution capability | | Customer types | B2C through grocery, convenience, e-commerce (including Coupang, after a 2022–2024 supply dispute was settled) and club stores. B2B covers food service, food manufacturers (sugar, flour, starch syrups), feed compounders and integrators (amino acids), and CPG companies (TasteNrich, nucleotides, PHA) | | End-markets | Packaged food (Korea, US, Japan, China, Europe, Oceania); animal nutrition (global swine and poultry); food ingredients; bioplastics; healthcare (marginal) | ### Company self-description (paraphrased) Recent IR and recruitment materials describe CJ CheilJedang as a global company that uses distinctive technology and core-materials competitiveness to lead a healthy, enjoyable "lifestyle food" culture and to provide solutions (CJ CheilJedang H2 2026 recruitment notice, September 2026). The FY2025 Sustainability Report, signed by CEO Yoon Seok-hwan, frames the year as one of strategic portfolio reorganization. ### Independent characterization CJ CheilJedang is best understood as three businesses with very different economics sharing one balance sheet: - **A structurally growing but low-margin global branded-food franchise.** FY2025 food operating margin was about 4.6%. It is driven by overseas K-food demand and is held back by a mature, price-regulated domestic market. - **A highly cyclical, capital-intensive commodity fermentation business.** Bio OP fell 36.7% in FY2025 and to KRW 5.5bn in Q1 2026. Its earnings swing with Chinese capacity additions, grain costs and feed-sector demand. **A logistics subsidiary:** It inflates consolidated revenue but contributes only 40.16% of its earnings to shareholders. The company's own strategy now treats branded K-food as the core and the remaining materials businesses as candidates for selective investment, harvest or exit.

Revenue$19.2B
Employees8,175
Market CapN/A
Founded1953
Seoul, South Korea
Citylabs

Citylabs Co., Ltd.

Premium
Information Technology

BFLABS is a small Korean public-sector ICT contractor. Its revenue base is the design, build and maintenance of Intelligent Transport Systems (ITS): traffic-information and CCTV control centres, bus information systems, and air-traffic and maritime-control information systems, sold mainly to local governments and state agencies under Korea's SOC (social overhead capital) procurement regime. Since 2018, successive controlling shareholders layered several strategies on that base: blockchain middleware (MiddleBlock DID / Blockchain-as-a-Service), smart-city pilots, insulated-glass production equipment through a subsidiary, web hosting, mobile-game publishing tied to crypto tokens, and a string of financial investments in listed affiliates (Carelabs, Daesan F&B) and a crypto exchange (Streami/GoPAX). The investment strategy, rather than the operating business, defined the company's recent history. Related-party and investment transactions produced three consecutive audit disclaimers, multi-party governance litigation and delisting from KOSDAQ in May 2026. Today it is a ~₩15bn-revenue, loss-making, unlisted ITS contractor with contested governance. --- ### Company's own description The company's DART business-overview summary, as reproduced by the k5.co.kr DART mirror, says it was established in 2006 as an ITS-construction specialist and has built a position in SOC work, ITS included. The business of the company and its subsidiaries, as described there, has four parts: 1. ITS integrated solutions and CCTV control-centre construction services. 2. Manufacture of insulated (multi-layer) glass production equipment. 3. Blockchain-based information/data processing. 4. Hosting and domain services. The same summary records a mobile-game publishing division created in September 2021. The S&P Global / Yahoo Finance profile, derived from company filings, lists the offering as: - Intelligent transportation and CCTV systems - Air-traffic and maritime-control systems - Bus information systems - Drone management systems - Electric-vehicle charging solutions - Smart environment solutions - Decentralised identity (DID) verification and digital-asset transaction services - MiddleBlock, a Blockchain-as-a-Service platform A company introduction on the LinkonBiz B2B portal describes the company in similar terms. It says the company has built and maintained intelligent information-management systems for roads, aviation and ports since 2006, that it positions itself in the U-City (ubiquitous city) and smart-city segment, and that after its 2021 renaming it aimed to become an IoT/AI/blockchain-based smart-city specialist. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Primary revenue model | Project-based system-integration contracts (build), plus multi-year operation and maintenance contracts | Hanam City BIS maintenance contract covering the centre system and 250 field devices (Asia Economy, 4 March 2021); THE VC counts 369 B2G contracts | | Product vs service mix | Predominantly services and integration. Equipment sales come mainly through the glass-equipment subsidiary (Aegis). | DART business overview via k5.co.kr | | Subscription / licensing | Marginal. MiddleBlock BaaS and DID APIs were marketed, but no recurring-revenue disclosure was found. | Asia Economy, 17 November 2021 | | Revenue recognition | Percentage-of-completion on construction-type contracts. Progress-rate estimation was one cause of the company's earlier investment-caution designation. | CEO Han Sang-woo interview (Asia Economy, 18 October 2024) | | Customer types | Central government agencies (e.g., Seoul Regional Aviation Administration), metropolitan and municipal governments (Hanam, Jeju and others), public enterprises; some private blockchain clients | Dealsite (1 February 2021; 16 August 2019); Asia Economy (4 March 2021) | | End-markets | Road traffic management, public transit information, aviation and port information systems, smart-city pilots, EV-charging infrastructure pilots, drone administration, environmental monitoring (fine dust, water quality) | Dealsite (16 August 2019; 1 February 2021) | | Value-chain position | Mid-tier prime contractor or consortium member in public procurement. Integrates third-party hardware (cameras, detectors, VMS signs) with its own centre software. | Independent assessment | ### Independent characterisation Underneath the frequent rebranding, the durable asset is a 20-year Korean public-sector ITS integration and maintenance franchise. It generates roughly ₩15–30bn a year of revenue at weak or negative operating margins. The blockchain, game, crypto-exchange and healthcare episodes were capital-markets strategies financed by convertible bonds and private placements. They did not grow organically from the core business. Their legacy is the governance failure that ended the listing: - impaired or opaque investments in associates - disputed related-party flows - unrecognised token holdings Gross margin is a reasonable ~52% (FY2025, S&P Global). SG&A on a ₩15bn revenue base, together with investment losses, keeps the company loss-making. Operating losses were recorded every year from 2015 onward except FY2020 (Newspim, 24 May 2024; Asia Economy, 11 March 2021).

RevenueN/A
Employees27
Market CapN/A
Founded2006
Anyang, South Korea
ChunLab

ChunLab, Inc.

Premium
Information Technology

| Metric | FY2023 | FY2024 | FY2025 | H1-2026 | |---|---|---|---|---| | Employees (headcount, period-end) | — | — | 124 | 83 | Note: the FY2025 column holds the end-June 2025 figure (124), as reported in a CJ affiliate headcount comparison. CJ Bioscience is the red-biotechnology (pharmaceutical and healthcare) arm of CJ CheilJedang. It was built on ChunLab, a Seoul National University spin-out that pioneered microbial genomics and bioinformatics. Its core intellectual capital is a precision microbial taxonomy platform (EzBioCloud, now the AI-augmented Ez-Mx platform), large Korean human-microbiome datasets, a strain library, and the discovery platforms (MicroRx, MicroDx) and candidates acquired from the UK's 4D pharma in 2023. From 2022 to 2025 the company positioned itself as a microbiome-therapeutics developer. Its lead asset, CJRB-101, an oral live biotherapeutic tested with pembrolizumab, was voluntarily terminated after Phase 1 in May 2026. Management has since rebalanced toward "Health & Wellness": personalised gut-microbiome testing and precision-nutrition solutions linked to CJ's health-functional-food business, alongside earlier-stage drug programmes (CJRB-201, CJRB-302, CJRB-401). Revenue is under KRW 4 bn a year against R&D spending above KRW 20 bn. The company depends on parent funding and faces tightening KOSDAQ listing-maintenance thresholds. --- ### What the company does CJ Bioscience works in two connected areas. **Microbial bioinformatics platform and solutions.** This is the original ChunLab business. ChunLab built a genome-based, high-resolution microbial reference database and cloud analysis environment, EzBioCloud. It offered next-generation sequencing (NGS) analysis services, bioinformatics software (CLcommunity, CLgenomics), and a "NGS/BI total solution" for academic, government and industrial customers. At the time of the IPO (2019), the company described its microbiome reference database as cited more than 8,500 times in the global literature. It also reported: - more than 120,000 human-microbiome data sets; - more than 5,924 novel taxa identified through its Precision Taxonomy Platform (as of August 2019). In 2019 it launched the beta version of TrueBac ID, described as the first genome-based solution for bacterial identification in infection diagnostics. At that time it was pursuing FDA clearance for TrueBac ID as Software as a Medical Device (SaMD). **Microbiome-based healthcare and therapeutics.** This includes: - consumer and clinical gut-microbiome monitoring (Smilebiome; the Pibio app-linked personalised probiotic service launched around 2020; and the "Smile Gut" (스마일 것) gut-microbiome test referenced by management in 2025); - since 2022, a drug-discovery pipeline of live biotherapeutic products (LBPs). After the CJ acquisition, CJ CheilJedang folded its existing red-bio assets (strain library, fermentation know-how, therapeutics research) into the company in January 2022. ### Revenue model | Revenue type (latest disclosed mix, Q2-2026) | Share of revenue (%) | |---|---| | Microbial bioinformatics platform & solutions (services/subscriptions/analysis) | 86 | | Microbiome-based healthcare (testing/consumer solutions) | 14 | | Licensing / milestone income | 0 | | Therapeutic product sales | 0 | Revenue is almost entirely service and solution revenue: - microbial genome analysis and bioinformatics solutions; - microbiome-based personalised healthcare services. Industry press summarising DART filings consistently describes revenue this way. A market-data summary of the Q2-2026 disclosure gives the revenue split as: - "microbial bioinformatics platform and solutions": 86%; - "microbiome-based healthcare": 14%. No product-sale revenue from approved therapeutics exists. No licensing (technology-transfer) revenue has been recognised: the 2024 target of three technology-out deals by 2026 had not been met as of October 2026. Source: Butler.works summary of company disclosures (Q2-2026 revenue basis). ### Value chain position The company sits upstream in the microbiome value chain, covering: - reference data, strain identification and taxonomy; - multi-omics analytics and biomarker discovery (Ez-Mx); - candidate discovery (Ez-Mx combined with 4D pharma's MicroRx); - early clinical development. It does not own GMP manufacturing for live biotherapeutics. At the IPO stage it had arranged CMO/CDMO cooperation with GC Green Cross (2019 MOU). In the wellness channel, it supplies science (testing, strain evidence, precision-nutrition algorithms). Consumer product commercialisation sits with group affiliates, notably CJ Wellcare, CJ CheilJedang's health-functional-food subsidiary formed in 2022. ### Customer types and end-markets | Customer type | Offering | End-market | |---|---|---| | Academic and government research institutes | EzBioCloud, NGS/BI analysis, national R&D projects | Life-science research tools & services | | Public-sector tenders | Microbial genome analysis | Government bioinformatics procurement (affected after CJ affiliation; see 2.5) | | Hospitals and clinics | Gut-microbiome analysis services (e.g., Mediram Korean Medicine Hospital, Sun Medical Center, BeautyOn Clinic) | Clinical/precision health | | Consumers (direct or via partners) | Smilebiome, Smile Gut testing, personalised nutrition (MAC solution planned H2-2026) | Consumer wellness / precision nutrition | | Pharma / biotech (target) | Licensing of LBP candidates and platform | Microbiome therapeutics | | Group affiliates (CJ CheilJedang, CJ Wellcare) | Strain/microbiome science for health-functional foods | Probiotics / functional foods | ### Company's own characterisation versus independent characterisation **Company's description.** Recent company language (2024 vision; 2025–2026 disclosures and press releases) has evolved: - At launch (Jan 2022): "Global No.1 microbiome company". - 2024 vision: "A global innovator in healthcare through AI-powered microbiome science", with the mission "Contributing to global health with ONLYONE therapeutics and solutions". - After the May 2026 termination of CJRB-101: the company says it will pursue drug development and a premium wellness business in parallel. It aims to strengthen a profitability- and cash-flow-centred structure based on validated strain assets and clinical data, building a microbiome-based "Health & Wellness" business. (Paraphrased from the company statement accompanying the 12 May 2026 disclosure.) **Independent characterisation.** CJ Bioscience is best described as a subscale microbiome bioinformatics service company carrying a parent-funded R&D programme whose most advanced clinical asset has now been discontinued. The facts behind this view: **Revenue fell after the acquisition:** Revenue declined from about KRW 5.3 bn (2020, pre-acquisition) to KRW 3.5–3.7 bn (2024–2025). Management attributed part of this to losing preferential access to public tenders once the company became a large-business-group affiliate rather than an SME. **Revenue is far below spending:** R&D expense of KRW 19–23 bn a year has run at roughly 4–7 times revenue. **The strategic logic now rests on wellness:** The company is converting its microbiome science into consumer and clinical wellness revenue inside the CJ ecosystem. That is lower-risk but also lower-value than the original licensing thesis.

Revenue$0.0B
Employees83
Market Cap$0.0B
Founded2009
Seoul, South Korea
Chunil

Chunil Express Co., Ltd.

Premium
Information Technology

Chunil Express is a 77-year-old, Busan-headquartered intercity express-bus operator. It is one of eight licensed Korean express-bus companies, which together run the national scheduled express-bus network. Its operating business has been loss-making every year since 2020. Revenue (KRW 45.6bn in FY2025) has recovered to only about three-quarters of pre-pandemic levels, gross margins sit in low single digits, and cash has fallen below KRW 1bn while short-term bank debt has risen. The equity story, however, is not the bus business. Chunil owns 16.67% of Seoul Express Bus Terminal Co. (SBT), making it the second-largest shareholder after Shinsegae Central City (70.49%). SBT owns the Banpo terminal site in Seoul's Gangnam corridor, which is now in pre-negotiation with the Seoul Metropolitan Government for a 60-storey mixed-use redevelopment. With about 86% of shares held by the founding family, the free float is roughly 200,000 shares. The stock has become one of Korea's most volatile redevelopment-theme equities. --- ### What the company does Chunil Express operates scheduled long-distance express-bus services across South Korea. Its fleet includes premium, deluxe ("udeung") and standard coaches [S20]. It also runs two ancillary activities: leasing space in its own building, and carrying small parcels and freight on its buses [S20][S22]. A November 2025 summary of the business report states that Chunil: - is one of eight national express-bus companies; - operates 125 routes; and - operates them under a system where trip frequencies on each designated route are jointly coordinated among carriers [S20]. Investing.com's company description puts the fleet at more than 180 express buses, mainly Hyundai Universe and Kia Granbird models [S22]. ### Business model and revenue model | Revenue stream | Nature | Model | Disclosure status | |---|---|---|---| | Express-bus passenger fares | Per-ticket fares on licensed routes; fares are regulated | Service (transactional) | Not separately disclosed in sources accessed; the dominant share of revenue by the company's own description | | Small-parcel / freight carriage on buses | Per-consignment fees | Service | Not separately disclosed | | Real-estate leasing (own building, Busan) | Rental income | Leasing | Not separately disclosed. Investment property carried at KRW 3.7bn, of which land is KRW 3.55bn (FY2025) [S4] | | Dividend income from SBT stake | Financial income (non-operating) | Investment | KRW 2.5bn recognised in FY2025; none in the trailing twelve months to June 2026 [S5][S6] | There is no product, subscription or licensing revenue. The business is close to a pure service model with high operating leverage. ### Cost structure (FY2025, from DART-derived cost-of-sales breakdown) | Cost line (FY2025) | KRW bn | % of revenue | |---|---|---| | Revenue | 45.6 | 100.0 | | Cost of sales – labour | 18.0 | 39.4 | | Cost of sales – fuel and materials | 10.0 | 21.9 | | Cost of sales – depreciation | 2.4 | 5.3 | | Cost of sales – other (tolls, maintenance, terminal fees, insurance etc.) | 13.5 | 29.6 | | Total cost of sales | 43.7 | 96.0 | | Gross profit | 1.8 | 4.0 | | SG&A (salaries KRW 4.8bn, retirement KRW 1.5bn, other) | 7.8 | 17.0 | | Operating loss | -5.9 | -13.0 | Source: [S5] (Valueline breakdown of the FY2025 DART income statement), [S2]. Labour and fuel together absorb more than 60% of revenue. Fares are regulated, so the company has little short-term pricing power to pass through wage or diesel inflation. ### Value-chain position, customers, end-markets **Value-chain position:** Chunil is an asset-owning operator (buses, drivers, route licences). It sells through industry-wide ticketing channels and terminals it does not control; for example, the Seoul terminals are owned by SBT and others. **Customers:** Retail travellers on business, commuting, leisure, holiday and military-leave trips; parcel shippers; commercial tenants. **End-market:** Korean intercity road passenger transport. It competes with KTX and SRT high-speed rail, conventional rail, domestic airlines on trunk routes, intercity (시외) buses, and private cars. ### Company's own description vs. independent characterisation **Company/filing description (paraphrased):** A passenger-transport company founded in 1949 and KOSPI-listed since 1977. It runs a nationwide express-bus business with premium, deluxe and standard services, and leases its own building [S20]. **Independent characterisation:** Economically, Chunil is now two businesses with very different value drivers: 1. **A structurally loss-making regulated bus operator.** It has posted operating losses in seven of the last nine years and burns roughly KRW 3–8bn of free cash a year [S2][S6]. 2. **A holding vehicle for a minority stake in prime Seoul real estate (SBT).** This stake is carried at about KRW 33bn on the balance sheet [S4]. Market participants attribute far higher value to it if redevelopment proceeds [S9]. The stock price since November 2025 reflects the second business almost entirely.

Revenue$0.0B
Employees279
Market CapN/A
Founded1949
Busan, South Korea
CHOSUN

CHOSUN WELDING POHANG Co., Ltd

Premium
Information Technology

Chosun Welding Pohang is a micro-cap, family-controlled Korean manufacturer of arc-welding consumables. It is the listed operating core of the CS Holdings group, whose roots go back to the 1949 founding of the wider Dongkuk Steel family of companies. From its single integrated plant in Pohang it makes covered (stick) arc electrodes, submerged-arc welding wire and copper-coated solid MAG wire, and it markets the group's full "Chosun Welding" brand range. Customers include shipyards, plant and construction contractors, machinery builders and automotive suppliers, and a large network of small fabricators served through distributors. Industry sources describe it as the domestic share leader in covered electrodes, a mature but certification-intensive niche. Commercially it is small: revenue is about KRW 52bn and has been contracting. Financially it is very strong: it has no borrowings, and cash plus short-term instruments exceed its entire market capitalisation. The investment debate centres less on growth than on the shipbuilding cycle, labour relations, and how the company handles a 26% treasury-share stake under Korea's 2026 mandatory-cancellation regime. --- ### What the company does The company makes and sells welding materials (용접재료). According to the company's own subsidiary profile, the Pohang entity produces covered arc welding electrodes (피복아크용접봉), submerged-arc welding wire (서브머지드 와이어) and solid wire for CO2/MAG welding (솔리드 와이어). It also sells "Chosun Welding" branded welding materials generally. Butler, drawing on the 1H2026 DART filing, attributes 100% of revenue to welding materials. ### Company's own description (business report, paraphrased) The company's DART business report, as summarised by ValueLine, describes the business as follows: - The company inherited the covered welding-materials division of the former Chosun Welding in the 2010 spin-off. - Welding is a foundational joining process for Korea's key industries: automotive, construction and shipbuilding. - The company considers its covered-electrode technology to be world-class and positions itself as a domestic leader in that category. - Its main products are covered arc electrodes and solid wire. These are used everywhere from small steel workshops to construction, machinery and chemical-plant projects. - Solid wire goes mainly to the automotive and construction-equipment industries. Competitiveness in solid wire depends on straightness-retention and copper-plating know-how. - Demand is sensitive to the cycles of downstream industries because the products are distributed as industrial materials. - The company acknowledges a technology gap with advanced-country makers in high-alloy and non-ferrous special alloys, and says sustained R&D is narrowing it. ### Independent characterisation **Business model:** 100% product sales of consumables. There is no service, subscription or licensing revenue. Welding consumables are used up during fabrication, which creates recurring replacement demand tied to fabrication volumes, not to installed equipment. **Value-chain position:** Mid-stream converter. - *Inputs:* the company buys steel wire rod (mainly from domestic integrated mills such as POSCO, whose Pohang works adjoins the plant), flux minerals and alloying powders, and copper for wire plating. - *Process:* drawing, coating/extrusion (electrodes), plating and spooling (wire). - *Outputs:* sold to end-users directly and through industrial distributors. **Customer types:** 1. Large shipbuilders and offshore yards. 2. EPC/plant fabricators (oil and gas, power, chemical). 3. Construction steel-structure and bridge fabricators. 4. Machinery, rolling-stock and automotive/auto-parts manufacturers. 5. Distributors serving small workshops. **End-markets served (per Simply Wall St company description):** shipbuilding, offshore, construction, oil and gas, nuclear energy, general fabrication, automobiles. **Group structure matters:** Product categories marketed under the Chosun Welding brand are split among sister companies under CS Holdings: - Flux-cored wire (FCW), SAW flux, and MIG/TIG wire: made by Chosun Welding Onsan (Ulsan, 100% owned by CS Holdings). - Overseas production and sales: Chosun Vina (Vietnam), Chosun Welding Japan, and Chosun Welding (Thailand). - Group logistics: CS Logistics. None of these are owned by the listed company. Investors in 120030 therefore own the stick-electrode and solid-wire franchise, not the faster-growing FCW franchise. This is a structural point often missed in screening databases that describe 120030 with the whole group's product list. **Balance-sheet model:** Unusually, more than 70% of total assets are financial (cash, short-term deposits/instruments and long-term investments). Financial income is therefore a large share of pre-tax profit; in FY2024, net income exceeded operating income.

Revenue$0.0B
Employees106
Market CapN/A
Founded1949
Pohang, South Korea
Choong

Choong Ang Vaccine Laboratory Co., Ltd.

Premium
Information Technology

CAVAC is a 58-year-old, family-controlled Korean veterinary biologics specialist. It develops, manufactures and sells vaccines for swine, poultry, dogs, cats, cattle and, from 2027, goats. The company is one of the few Korean-owned firms with an integrated R&D-to-GMP vaccine platform in a domestic market that multinationals (Boehringer Ingelheim, Zoetis, MSD, Ceva and others) have historically dominated with a share of more than 70%. Its franchise brands are SuiShot (swine), FowlShot (poultry), CaniShot and FeliShot (companion animals) and BoviShot (cattle). Revenue was KRW 49.1 bn in FY2025 with an operating margin of about 13%, and the balance sheet holds net cash of about KRW 17 bn. The company has three equity-story pillars. The first is a steady domestic livestock-vaccine business, part of it sold through government procurement. The second is a growing export channel covering 20+ countries, with first-of-kind Korean entries into China and Brazil for Suishot Circo-ONE. The third is optionality from an export-licensed live attenuated African swine fever (ASF) vaccine, SuiShot ASF-X, which is awaiting registration in Vietnam and the Philippines. --- ### What the company does CAVAC manufactures and sells biological preparations, mainly vaccines, that prevent infectious disease in production animals and companion animals. The company describes itself as a leading developer of animal biological medicines. Its self-description emphasises long accumulated expertise and a range of manufacturing technologies, including toxoid, subunit and recombinant vaccines. Its stated flagship disease areas are classical swine fever, porcine epidemic diarrhoea (PED), highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) and low-pathogenic avian influenza (LPAI). The company is also developing user-friendly delivery formats, including needle-free, drinking-water, oral and spray administration (company overview as summarised by ValueLine from the business report). ### Business and revenue model The revenue model is almost entirely product sales: finished vaccine vials or doses sold per batch after national lot-release approval from the Animal and Plant Quarantine Agency (APQA). Three secondary streams sit alongside it: 1. **Contracted services (용역)**: contract research, disease testing and biologics studies. About 4% of revenue in Q2 2026 (Butler, citing the business report product mix). 2. **Government procurement and distribution**: supply under Public Procurement Service (PPS) tenders. This includes vaccines CAVAC makes and, since 2026, vaccines it imports and distributes. An example is a KRW 5.81 bn SAT1 foot-and-mouth disease (FMD) vaccine contract signed 8 July 2026. CAVAC said it would import that volume from overseas manufacturers (Edaily, 8–9 July 2026). 3. **Licensing and distribution partnerships abroad**: for example, an exclusive distribution agreement under which Elanco China sells Suishot Circo-ONE. The contract terms are not publicly disclosed. CAVAC has no subscription or royalty income of any significance that has been disclosed. ### Sales channels The most recent channel split found is from the 2019 NICE technology analysis report, using FY2018 data. That year, sales through dealers and agents were 44.2% of revenue, government supply through the PPS was 26.3%, and exports were 27.2%. Management has stated a long-term ambition to raise exports to 60% of revenue (BioBook Media, August 2026). ### Customers and end-markets | End-market | Customer type | Notes | |---|---|---| | Swine production (Korea and export) | Integrated pig producers, farm veterinarians, dealers; overseas distributors (Elanco China; partners in Brazil, Thailand, Vietnam) | Largest product family; about 50% of Q2 2026 revenue | | Poultry (broilers, layers, breeders) | Integrators (for example Harim, a development partner), hatcheries, layer farms | About 28% of Q2 2026 revenue | | Companion animals (dogs, cats) | Veterinary clinics via distributors | About 11% of Q2 2026 revenue | | Cattle and small ruminants | Beef and dairy farms; goat farms from 2027 | Cattle about 4% of Q2 2026 revenue | | Government animal-disease control | MAFRA via PPS | Emergency and stockpile tenders, such as SAT1 FMD in 2026 | | Contract services | Government, academia, industry | About 4% | ### Value-chain position CAVAC is vertically integrated across seed-strain development, antigen production (cell culture and bioreactors), formulation (including its proprietary adjuvant CAvant), filling, freeze-drying, labelling and quality control under KVGMP. Production takes place at Plant 1 in Daejeon and at Plant 2 in Nonsan, which handles poultry vaccines and animal testing. For live ASF virus, Korean rules require BL3 containment. CAVAC has no such facility, so its ASF vaccine was licensed on a contract-manufacturing basis at a GMP site in Hanoi, Vietnam (DailyVet, April 2026). ### Independent characterisation CAVAC is best understood as a niche, cash-generative biologics manufacturer with embedded R&D optionality. Its core domestic business grows in the mid-single digits and is exposed to livestock cycles and disease outbreaks. It is profitable (operating margin 11–17% over FY2021–FY2025), heavily capitalised relative to revenue (equity of KRW 105 bn against revenue of KRW 49 bn) and conservatively financed. Inventory intensity is a structural feature of vaccine manufacturing: work-in-progress and semi-finished antigen are held for long periods. Inventory reached KRW 22.0 bn at end-FY2025, or about 45% of annual revenue. The market values CAVAC below book value (P/B about 0.77×), which suggests investors are not paying for the ASF or FMD options.

Revenue$0.0B
Employees194
Market CapN/A
Founded1968
Daejeon, South Korea
Chong

Chong Kun Dang Pharmaceutical Corp.

Premium
Information Technology

Chong Kun Dang is Korea's third-largest traditional pharmaceutical company by 2025 revenue (KRW 1.69 trillion), behind Yuhan and GC Biopharma and ahead of Kwangdong, Daewoong and Hanmi. Its business model combines a large domestic prescription-drug sales force with a portfolio of in-house branded generics and incrementally modified drugs, a handful of domestically discovered new chemical entities, and a heavy and growing book of in-licensed and co-promoted multinational products — currently led by Novo Nordisk's obesity drug Wegovy, Amgen's Prolia and Evenity, MSD's Januvia family and Atozet, and Bayer's Eylia. The company is attempting a strategic pivot from "best-in-Korea commercial partner" to "global innovator", underpinned by the 2023 out-licensing of HDAC6 inhibitor CKD-510 to Novartis (up to USD 1.305 billion), a first-in-house ADC (CKD-703) in US Phase 1/2a, a new NRDO subsidiary (Achella), and a planned KRW 2.2 trillion bio-research complex in Siheung-Baegot. Margins have compressed sharply as low-margin merchandise grows. --- ### What the company does Chong Kun Dang develops, manufactures, imports and markets human pharmaceuticals, overwhelmingly for the South Korean market. Its revenue is drawn from three sources that management and Korean sell-side analysts track separately: 1. **Own products (제품)** — drugs manufactured by the company, including branded generics, fixed-dose combinations and incrementally modified drugs (e.g., Telminuvo), Korean-origin new drugs (e.g., Duvie/lobeglitazone; Camtobell/belotecan), biosimilars (e.g., Nesbell/darbepoetin alfa) and OTC brands (e.g., Penzal). 2. **Merchandise (상품)** — finished products bought from licensors or partners and resold, and products co-promoted with multinational and domestic companies (Wegovy, Prolia, Evenity, Januvia/Janumet, Atozet, Prevenar, Eylia, Godex, Dilatrend, Fexuclue, Gliatilin under licence from Italfarmaco). 3. **Licensing and milestone income** — technology-transfer revenues, most visibly the USD 80 million upfront payment from Novartis for CKD-510 recognised in FY2023 and a development milestone received in May 2025. ### Business and revenue model The company is fundamentally a product-sales business (prescription and OTC drug sales to hospitals, clinics, wholesalers and pharmacies) supplemented by episodic licensing income. It has no subscription or service revenue of note. Its competitive engine is a nationwide medical-representative network with deep coverage of primary-care clinics in cardiometabolic disease (hypertension, dyslipidaemia, diabetes), which multinational originators rent through co-promotion contracts. This explains the most important structural fact about Chong Kun Dang's P&L: as co-promoted merchandise grows, revenue rises but gross margin falls, because the company books the gross sale while keeping only a distribution/promotion margin. The dynamic is visible in the numbers. Gross margin was 39.7% in FY2023 (boosted by the Novartis upfront), 33.6% in FY2024 and 31.1% in FY2025, and Korean press reports a cost-of-sales ratio in the low-70% range in Q2 2026 versus the high-60% range a year earlier (Money Today, 5 Aug 2026; Dailian, 31 Jul 2026). A 2026 Korea Ratings analyst comment (via New Daily, 6 Jul 2026) characterised the expected trajectory as sustained top-line growth from new co-promotions (Wegovy, Godex, Fexuclue) but profitability below 2023–2025 levels because of the rising merchandise mix. ### Value-chain position Chong Kun Dang is vertically integrated across formulation development, finished-dosage manufacturing (principally at its Cheonan plant), regulatory affairs and domestic commercialisation. Active pharmaceutical ingredients are largely sourced externally or from sister companies (Chong Kun Dang Bio and Kyongbo Pharm, both controlled by Chong Kun Dang Holdings, not by the listed company). Discovery research is conducted at the Hyojong Research Institute in Yongin, Gyeonggi Province. In licensing deals the company acts as an early-to-mid-stage originator (CKD-510 was out-licensed after Phase 1) rather than a late-stage global developer. ### Customers and end-markets Customers are Korean hospitals (tertiary, general), primary-care clinics, pharmacies and pharmaceutical wholesalers, with reimbursement determined by the National Health Insurance Service (NHIS) and Health Insurance Review & Assessment Service (HIRA). End-markets by therapy: cardiovascular/metabolic (the core franchise), obesity (Wegovy since Oct 2025), bone health (Prolia, Evenity), CNS/cognition (Gliatilin), vaccines (Prevenar), ophthalmology (Eylia, from Dec 2025), hepatology (Godex), gastroenterology (Fexuclue), oncology and transplant/immunology. Exports and overseas sales are small; a geographic split was not found in the sources reviewed. ### Company self-description vs independent characterisation **Company framing (paraphrased from the March 2026 AGM address by CEO Kim Young-joo):** the company sustained growth through its established and newly introduced products, accepted lower profit in exchange for higher R&D investment, and will pursue "substantive" profit growth in 2026 through timely launches, product competitiveness and market responsiveness, while using the NRDO subsidiary Achella to raise R&D efficiency and building the Baegot bio complex to reach global-level bio capability (Dailypharm and Medifonews, 26 Mar 2026). **Independent characterisation:** Chong Kun Dang today is best understood as a high-revenue, low-margin domestic commercial platform with an option on a small number of global R&D assets. Roughly a third of revenue appears to come from the top handful of in-licensed brands; Wegovy alone was the company's largest product in Q1 2026 at about KRW 48.8 billion (New Daily, 6 Jul 2026), around 11% of standalone quarterly sales. Organic own-brand growth is modest and under regulatory pressure (choline alfoscerate re-evaluation; the August 2026 generic price reform). The equity story therefore rests on (a) Novartis's progress with CKD-510 in atrial fibrillation, (b) CKD-703's early clinical data, and (c) management's ability to fund a KRW 2.2 trillion research complex without impairing a balance sheet that has moved from net cash to modest net debt.

Revenue$1.2B
Employees2,304
Market CapN/A
Founded1941
Seoul, South Korea
Chonbang

Chonbang Co., Ltd.

Premium
Information Technology

Chonbang is one of Korea's oldest cotton spinners, descended from a 1935 Japanese-era mill in Imdong, Gwangju, and formally launched as Chonnam Spinning in 1953. For decades it was a mid-sized, vertically integrated producer of cotton and blended yarns, sewing and embroidery threads, woven fabrics, denim, knits and indigo-dyed yarns. Since 2017 it has executed a sustained retrenchment: five production sites (Siheung, Gwangju-Imdong, Cheonan, Yeongam, Iksan) were idled between 2017 and 2023, and the Imdong and Cheonan sites were sold for a combined KRW 422bn, recognised in FY2022. Revenue fell from KRW 200.8bn (2016) to KRW 40.8bn (2025), with operating losses in every year since 2022. The company is now a small, debt-free textile operator with roughly 80 employees, a cash-rich balance sheet (KRW 83.9bn cash and short-term investments at Q3 2025), a price-to-book ratio near 0.22–0.26x, and a 32% treasury-share block that newly enacted Korean law requires it to address. --- ### What the company does Chonbang manufactures and sells textile products in South Korea. The product scope historically disclosed by the company and reproduced by Simply Wall St comprises yarns; embroidery and sewing threads; woven fabrics including cotton and wool; denim; knits; indigo-dyed yarns; and the manufacture and sale of clothing products. As of the second quarter of 2026, the company's revenue was classified 100% as "spinning/weaving" (방직업) in DART-derived segment data (Butler), meaning no separately reported leasing, retail or other segment contributes to revenue. ### Business model and revenue model | Revenue model element | Estimated share of revenue (FY2025) | Basis | |---|---|---| | Product sales (yarn, thread, fabric, related goods) | 100% | Butler segment data (Q2 2026: 방직업 100%) | | Services | 0% (not disclosed) | — | | Subscription | 0% | — | | Licensing / royalties | 0% | — | | Rental income | Not separately disclosed; KoalaGains asserts a 20–25% real-estate leasing contribution, which conflicts with DART-derived segment data showing 100% textiles. The DART-derived figure is preferred | Butler vs KoalaGains (discrepancy flagged) | The business model is a classic business-to-business commodity textile model: the company buys raw cotton and other fibres (predominantly imported, as Korea grows no commercial cotton), converts them into yarn and, historically, into fabric, and sells these intermediate goods to apparel makers, weavers, knitters and garment converters. Revenue is essentially 100% product sales; there is no disclosed service, subscription or licensing revenue. ### Value-chain position Chonbang sits in the upstream-to-midstream portion of the textile value chain: fibre (purchased) → spinning (core competence) → weaving/dyeing (largely exited with the April 2023 Yeongam shutdown) → garment manufacturing (historically limited clothing activity) → brands/retail (not present). After the 2023 closures, the company's remaining activity is concentrated in yarn and related products, which is the most commoditised and price-competitive link in the chain. ### Customer types and end-markets Customers are domestic and, to an undisclosed extent, export buyers of yarn and fabric: weavers, knitters, denim mills, thread converters and apparel manufacturers. End-markets are apparel (casual wear, denim, knitwear), home textiles and industrial thread. Customer concentration, export share and named customers are not publicly disclosed in retrievable sources. ### The company's own description vs. independent characterisation The company's self-description, as relayed through Simply Wall St and Stockopedia, is that of a Korea-based company principally engaged in manufacturing and selling textile products, including yarns, threads, woven fabrics, denim and knits. **Independent characterisation.** In economic substance, Chonbang today is a sub-scale, loss-making domestic spinner in managed decline, wrapped around a large cash balance generated by the monetisation of legacy factory land. The operating business generated KRW 40.8bn of revenue and an operating loss of KRW 7.3bn in FY2025 (Butler). The equity value of the company is dominated by its net cash and residual tangible assets, not by the earnings power of its mills. The key strategic questions for stakeholders are therefore capital-allocation questions — whether cash is returned, reinvested or consumed by operating losses, and how the 32% treasury-share block is resolved — rather than questions of market share or product innovation.

Revenue$0.0B
Employees78
Market CapN/A
Founded1935
Seoul, South Korea
Chokwang

Chokwang Paint Co., Ltd.

Premium
Information Technology

Chokwang Paint is a third-generation, family-controlled Korean coatings manufacturer founded in Busan in 1947 and listed on KOSPI since 1976. Korean research houses describe it as roughly the fifth-largest domestic paint maker, behind KCC, Noroo, Samhwa (SP Samhwa) and Kangnam Jevisco. Its business is weighted toward business-to-business industrial coatings — UV-curing coatings for electronics and plastics, powder coatings, general industrial and wood coatings, and automotive refinish (the "Zabo" brand) — with architectural paints a minority. Its single most valuable asset is arguably not an operating division but a 50% stake in Chokwang Jotun, a marine and protective coatings joint venture with Norway's Jotun, which is equity-accounted and has driven reported profits. Since 2018, management under Yang Seong-ah has pushed into advanced materials, chiefly battery thermal interface materials through subsidiary CK EM Solution. That pivot has so far absorbed capital and depressed group earnings, leaving a sub-0.3x price-to-book micro-cap with heavy treasury holdings. --- ### What the company does Chokwang Paint formulates, manufactures and sells paints, coatings and related chemical products. International data vendors summarise the portfolio as architectural, floor and waterproofing, heavy-duty, industrial, wood, plastic and UV-curing paints, plus powder coatings, adhesives, electronic materials, car-maintenance products and energy-saving products (Yahoo Finance and Simply Wall St company descriptions). Morningstar's shorter description emphasises floor paint, water repellents, residential, industrial and carpentry paints. The SEMI member directory, which Chokwang joined on 27 March 2026, now positions it as a KOSPI-listed chemical company offering coating solutions and advanced chemical materials for industrial and consumer markets — a deliberate re-framing toward materials. ### Company's own description The company's corporate brochure (Korean/English, reproduced in a K-Startup programme attachment) frames its mission around realising chemical technology that advances human progress. It states that, on technology accumulated since 1947, it produces high-functional and eco-friendly coatings for architectural, woodworking, industrial and automotive applications, as well as higher-value products for IT and new-materials industries, and that it invests in R&D through specialised research teams with the goal of becoming a world-class chemical company. Its long-standing management philosophy, reproduced in recruitment profiles, is to create an environment that enriches human life and contributes to human development; its stated aspirational targets were to become one of the top three domestic paint makers, first in revenue per employee, and to achieve an operating margin above 15%. The latter target is far from current reality (FY2025 operating margin of approximately −9.6%, derived). ### Business model and revenue model The revenue model is almost entirely product sales. There is no material subscription, licensing or service revenue disclosed. Revenue is generated through (a) direct B2B supply of industrial, UV, powder and plastic coatings to manufacturers (electronics, furniture, appliances, automotive parts), (b) distributor and dealer channels for architectural and auto-refinish products, and (c) export and overseas subsidiary sales. KoalaGains' business analysis (February 2026) characterises the model as a specialised B2B coatings supplier whose customers are typically large electronics and furniture manufacturers, with weaker positioning in brand-driven architectural paint. A second, non-consolidated earnings stream comes from the 50%-owned Chokwang Jotun joint venture. Per the Korea IR Council (December 2024), this JV appears in the separate (parent) accounts only as dividend income and in the consolidated accounts as equity-method income. This structural feature means consolidated operating profit materially understates the economic earnings power of the group's coatings franchise in good shipbuilding years. A third stream, still nascent, is advanced materials (battery thermal interface materials, EMI shielding, semiconductor encapsulation-related materials, display adhesives) housed mainly in CK EM Solution. ### Value chain position Chokwang sits in the mid-stream formulation layer: it buys resins, pigments, solvents, additives and petrochemical intermediates and converts them into formulated coatings and adhesives. It also produces some of its own resins (the Eumseong site includes a paint-and-resin plant). It is therefore exposed to petrochemical feedstock prices and the KRW/USD exchange rate on the input side; News1 (2024) attributed the FY2023 return to operating profit primarily to lower oil prices and stabilising raw material costs. ### Customer types and end-markets | End-market | Products | Evidence | |---|---|---| | Electronics / IT (mobile, appliance, display) | UV-curing coatings, plastic coatings, display polarizer UV adhesives | Segment mix (UV 17–28% of sales); Daishin (Dec 2024) on polarizer adhesives | | Furniture / woodworking | Wood coatings | Segment mix (wood 4.4%, 9M 2024) | | General industry / machinery / steel structures | Industrial coatings, powder coatings, heavy-duty coatings | Segment mix (industrial 23.5–25%; powder 14–15%) | | Construction (residential, commercial, floors, waterproofing) | Architectural paint, floor coatings (e.g., "Ice Deck"), waterproofing | Segment mix (architectural 13.7–20%); KoreaScience profile (2007) | | Automotive aftermarket | Auto refinish ("Zabo"), car-care products | Segment mix (auto refinish 9.3–10%) | | EV batteries / ESS / semiconductors | TIM adhesives, insulation, structural adhesives, binders, EMI/EMC solutions (via CK EM Solution) | Korea IR Council (Dec 2024); Financial News (May 2026) | | Marine / offshore (via JV, not consolidated) | Protective and anti-corrosion coatings | Chokwang Jotun company profile | ### Independent characterisation Chokwang is best understood as three businesses of very different quality under one listed shell: (1) a mature, low-margin, sub-scale domestic coatings business with genuine niche strength in UV and powder coatings; (2) a high-quality, cash-generative but minority-controlled (50/50) marine coatings JV whose earnings are captured below the operating line; and (3) a capital-hungry, loss-making advanced-materials start-up whose commercial success depends on winning and holding battery-maker qualifications in Korea, Hungary and the US.

RevenueN/A
Employees485
Market Cap$0.0B
Founded1947
Busan, South Korea
Chokwang

Chokwang Leather Co., Ltd.

Premium
Information Technology

Chokwang Leather is a nine-decade-old Korean tannery that converts imported raw hides into finished leather for automotive interiors (seat covers, headrests, armrests, steering wheels, knobs, door trims, dashboards) and for fashion goods (shoes, handbags, wallets, belts) and furniture. Its manufacturing business is small and shrinking — revenue fell from KRW 198.6 bn in FY2016 to KRW 97.9 bn in FY2025 — and employs just 116 people at its Cheongju complex. Economically, however, the company is now better described as a closely held investment holding vehicle with a residual tannery attached: at end-FY2025, investment securities (including Apple, Berkshire Hathaway and a Vanguard S&P 500 fund) represented roughly 72% of total assets, while operating assets were under 9%. The equity story is dominated by governance — a 46.57% treasury-share stake, no dividends since FY2022, a 15-year dispute with activist shareholder Park Young-ok, and Korea's 2026 mandatory treasury-share cancellation law. --- ### What the company does Chokwang Leather manufactures and sells finished leather. Its process spans the purchase of raw hides (predominantly imported bovine hides, per the company's industry classification and trade-data codes under HS 41 "raw hides and skins and leather"), tanning, re-tanning, dyeing and finishing, followed by sale of finished leather "fabric" (원단) to downstream converters. Morningstar's company description lists two product families: automotive leather for seat covers, headrests, armrests, steering wheels, knobs, door trims and dashboards; and fashion leather for shoes, bags, wallets and belts. Simply Wall St (S&P Global data) adds furniture leather. The company's Korean IR registration (IRGO) lists its main products as leather (leather fabric, footwear leather, car-seat leather), bags and footwear manufacturing and wholesale, under the KSIC industry "manufacture of leather, bags and similar products". ### Company's own description Chokwang does not publish an English annual report. Its DART filings (as summarised by ETF Shopping and Butler) describe it as a domestic producer of leather fabric, with revenue composition of leather fabric 99% and by-products 1% (Butler, 2Q2026 revenue basis). ETF Shopping's DART-derived profile characterises the company as a traditional materials business that processes leather for footwear and automotive seats, with a meaningful exposure to automotive seat leather and direct sensitivity of costs to raw-hide prices. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue model | ~100% product sales (finished leather); no service, subscription or licensing revenue | Butler 2Q2026 mix: leather fabric 99%, by-products 1% | | Non-operating income streams | Rental income from investment property (KRW 3.18 bn FY2025), dividend income (KRW 1.08 bn), interest income (KRW 1.30 bn), FX gains | Valueline income statement, FY2025 | | Value-chain position | Midstream processor: buys commoditised raw hides (upstream meatpacking by-product), sells to cut-and-sew/seat makers and fashion goods manufacturers (downstream) | Product description; industry structure | | Customer types | B2B: automotive seat and interior trim suppliers; footwear, handbag and leather-goods makers; furniture makers | Morningstar; Simply Wall St | | Named customers | Not publicly disclosed in sources reviewed | — | | End-markets | Automotive interiors (primarily Korean vehicle production), fashion footwear and accessories, furniture | Morningstar; ETF Shopping | | Geographic orientation | Overwhelmingly domestic; disclosed exports were KRW 0.6 bn in FY2025 per Valueline's line-item extraction | Valueline, FY2025 | ### Independent characterisation Three facts reframe the business: 1. **The tannery is the minority of the economic value.** At 31 December 2025, investment assets were KRW 475.7 bn, investment property KRW 79.1 bn and cash KRW 51.3 bn, against operating assets (trade receivables KRW 13.7 bn, inventory KRW 23.9 bn, PP&E KRW 17.5 bn) of roughly KRW 55 bn — about 8% of the KRW 662.0 bn balance sheet (Valueline, FY2025; analyst-computed shares). SmartToday, citing 3Q2025 data, reported that PP&E was just 2.8% of total assets while investment assets were 91.2% (on a broader definition), and activist shareholder Park Young-ok has publicly characterised the company as having turned into a de facto closed-end investment company. 2. **The tannery has shrunk by half in a decade.** Dealsite reported revenue declining from KRW 180.5 bn in 2015 to KRW 90.2 bn in 2024, with employee numbers down about 40% over the same period. DART data show a peak of KRW 198.6 bn in FY2016. 3. **Earnings are increasingly non-operating.** In FY2025, operating income was KRW 8.8 bn, but pre-tax income was KRW 14.1 bn, with the KRW 5.3 bn gap supplied by rent, dividends, interest and FX. More importantly, other comprehensive income (unrealised gains on equity holdings, which bypass the income statement) was KRW 22.9 bn in FY2025 and KRW 78.6 bn over the twelve months to June 2026 — dwarfing reported net income (Valueline). The appropriate analytical lens is therefore a sum-of-the-parts holding-company framework with a governance discount, rather than an auto-parts earnings multiple.

Revenue$0.1B
Employees116
Market CapN/A
Founded1936
Cheongju, South Korea
Choil

Choil Aluminum Co., Ltd.

Premium
Information Technology

Choil Aluminum is South Korea's second-largest producer of flat-rolled aluminium sheet, coil and plate, and one of its oldest. The company operates a single integrated rolling complex in Gyeongsan, North Gyeongsang Province, which includes a wide-width hot rolling mill commissioned in January 2016. Effective annual output is around 160,000 tonnes, against roughly 470,000 tonnes for the market leader, Novelis Korea (IB Tomato, Aug 2026). The company sells semi-finished rolled products to converters in packaging foil, HVAC fin stock, electrical and electronic components, construction, automotive, kitchenware and closures. Since 2021 it has repositioned toward lithium-ion battery supply chains, supplying aluminium foil stock to cathode-foil makers Lotte Aluminium and Dongwon Systems. It has a KRW 1.04 trillion long-term contract with Lotte Aluminium covering 2023–2027. The business earns thin conversion margins of 2–5% at the operating line. Its earnings are highly sensitive to LME aluminium prices and inventory timing. It carries a mainly short-term, trade-finance-driven debt load and has a controlling family shareholder. In 2026 it launched its first formal shareholder-value programme. --- ### The company's own description In its corporate materials and regulatory profile, Choil Aluminum describes itself as a specialist aluminium sheet manufacturer with the longest history in Korea's aluminium industry. It says it has pursued only rolled aluminium since its founding, and that it has steadily improved quality, introduced modern equipment, and built competitiveness on accumulated technical know-how. Its stated corporate motto stresses mutual cooperation, technological innovation and human-resource development. Its stated ambition is to be recognised in both domestic and global markets through customer satisfaction and an effective, efficient management system (company profile reproduced on TheTeams.kr). The regulatory business description, as summarised by Morningstar, says the company makes wide-width rolled products. These serve as input material for: - foil stock - fin stock - secondary-battery cathode foil stock - condenser (capacitor) case stock - nameplates - polypropylene (PP) closure caps - building interior and exterior materials - automotive materials - soundproof wall panels - printing (litho) plates - insulation materials - cosmetic caps - electronic components - kitchenware S&P Global's description groups the end-markets into secondary batteries, automobiles, aluminium foils, electrical and electronic components, construction materials, PP caps and railroad products. ### Independent characterization Choil Aluminum is a mid-stream semi-fabricator in the aluminium value chain. It has no upstream exposure: no bauxite, alumina or smelting. It buys primary aluminium ingot and slab, much of it imported and financed through letters of credit (Asia Economy, Oct 2021). It then converts the metal through melting and casting or slab reheating, wide-width hot rolling, cold rolling, annealing and finishing into coil, sheet and circles. These are sold to downstream fabricators, who turn them into final products such as cathode foil, fin stock, closures and building panels. **Revenue model.** Revenue is essentially 100% product sales. There is no service, subscription or licensing income. Butler.works classifies the single reporting segment, "aluminium plate" (알미늄판), as 100% of revenue in Q2 2026. Pricing in this industry is normally a pass-through of the metal cost (an LME-linked aluminium price plus regional premium) plus a conversion fee. Gross margin therefore measures how much conversion value the company captures, not the value of the metal itself. Gross margins of 4.5–6.6% over FY2021–FY2025 (S&P Global) confirm a commodity-processing economic model. In 2021 Hana Financial Investment argued that Choil held a favourable position in its product price-setting structure, so rising aluminium prices could support profitability (Economist.co.kr, Sep 2021). **Earnings sensitivity to metal.** Two mechanisms make reported profits pro-cyclical with aluminium prices: **Inventory lag:** metal bought earlier at lower prices is sold at current, higher prices, producing gains when prices rise and losses when they fall. **Volume-driven absorption of fixed costs:** In November 2024 company management told IB Tomato that the Q3 2024 profit improvement came mainly from higher aluminium material prices and could not really be attributed to battery-material growth. The 2009 accounts showed the reverse effect: operating and net losses were attributed to falling raw-material prices and inventory valuation losses (eToday, Apr 2010). **Customer types and end-markets.** Customers are industrial converters, not end consumers. Disclosed relationships include: **Lotte Aluminium:** (Lotte Group chemicals division; cathode foil, packaging foil). Plants in Ansan (Korea) and Tatabánya (Hungary, 18,000 t/yr cathode foil), plus a 36,000 t/yr US joint-venture project with Lotte Chemical in Kentucky (News Tomato, Dec 2022). **Dongwon Systems:** (cathode foil and packaging materials). Together, these two customers were 45% of Choil's revenue in Q3 2024, up from 37% in Q3 2023 (IB Tomato, Nov 2024). The rest of the book serves traditional markets: HVAC fin stock, packaging foil stock, condenser cases, PP and cosmetic caps, litho plates, building panels and soundproof walls, automotive sheet, electrical insulation and mould transformers, kitchenware circles, and railway applications. **Value-chain position.** The company sits at the less visible "back end" of the battery supply chain. In August 2026 industry participants told IB Tomato that value creation and investor attention concentrate further downstream, which partly explains the company's low market profile.

Revenue$0.3B
Employees363
Market CapN/A
Founded1975
Gyeongsan, South Korea
Choheung

Choheung Corporation

Premium
Information Technology

Headcount rose 48.5% over FY2021–FY2025 while separate-basis revenue per employee rose from KRW 0.7bn to KRW 0.9bn, indicating that hiring tracked a genuine expansion of output rather than overhead creep. Average tenure was 5.1 years in FY2025 and total payroll KRW 29.4bn, or 6.1% of separate revenue of KRW 481.7bn [ETF]. Third-party headcounts differ (Morningstar 464, Statbase 472, Simply Wall St 495, Investing.com 505); the DART figure of 533 is used as authoritative. Choheung is a mid-sized Korean B2B food-ingredient manufacturer and the industrial "engine room" of the Ottogi Group for cheese, bakery ingredients and frozen pizza. Founded in 1959 as a saccharin and chemicals maker, it exited chemicals in 1997 and rebuilt itself around yeast, bread creams, sweeteners (the long-running New Sugar product sold under the Ottogi brand), natural and processed cheese (Codano brand, acquired 2001) and, since 2016, contract production of Ottogi's frozen pizzas. Revenue nearly doubled from KRW 250.9bn in FY2021 to KRW 488.2bn in FY2025, but on wafer-thin margins (FY2025 operating margin 3.8%) financed by heavy short-term borrowing (total debt KRW 289.3bn at June 2026). Ottogi has consolidated Choheung since Q4 2022. In 2026 the company agreed to buy whey-powder and probiotic-strain specialist Samik Dairy for KRW 27.5bn, its first sizeable diversification move in two decades. --- ### What the company does Choheung manufactures and sells food ingredients and processed foods in Korea. Its disclosed product universe spans baking ingredients (fresh and instant yeast, beer yeast, beta-glucan, baking powder, bread conditioners), baking creams and vegetable creams, sweeteners, natural, shredded and processed cheese, processed butter, food-service sauces, frozen pizza and dough, and meal kits [MS][JP][SWS]. Its products are used principally in baking, confectionery and pizza [MS]. ### Company's own characterisation The company's self-description (as submitted to recruitment platforms and reflected in its business report) presents Choheung as a maker of food and food additives since 1959 that operates automated production lines in the Sihwa industrial complex in Ansan, producing cheese, frozen pizza, food-service sauces, bread cream and yeast, and that emphasises ethical management, environmental and safety responsibility and shareholder value [JP]. A DART-based summary of the latest (H1 2026) business report characterises Choheung as a specialist in bakery raw materials and cheese processing, producing health-oriented inputs (organic, additive-free, low-salt), premium cheese, natural sourdough starters and plant-based ingredients, with bakeries and coffee chains as principal outlets; it highlights flour, cheese and butter price volatility and KRW weakness as the main margin pressures, and rising demand for high-protein, low-sugar and high-fibre formulations as a growth driver [VL]. ### Reporting segments (latest disclosure) Choheung reports two segments: Cheese (≈60% of Q2 2026 revenue) and Food additives (≈40%) [BW, Q2 2026 DART half-year report]. ### Revenue model | Revenue type | Share | Evidence | |---|---|---| | Product sales (manufactured goods) | ≈100% | All disclosed revenue is operating revenue from goods [SA] | | Contract manufacturing / OEM for affiliate | Material, not quantified | Choheung has produced Ottogi-branded frozen pizza since 2016 [TW][SM] | | Branded B2B (Codano cheese, Mattone pizza, Ottogi-brand New Sugar and yeast) | Material, not quantified | [TW][FS] | | Services, subscription, licensing | None disclosed | — | ### Value-chain position and customers Choheung sits in the middle of the dairy and bakery value chain: it imports bulk cheese and dairy raw materials (for example New Zealand Fonterra mozzarella and cheddar and US string cheese supplied onward to Pizza Alvolo [INS]), then processes, shreds, blends, packages and freezes them, and also manufactures finished frozen pizzas. Raw materials consumed were equivalent to roughly 75% of revenue on a trailing basis to December 2025 (KRW 365.4bn of KRW 488.2bn) [VL], which explains why gross margin is structurally around 10%. Customer types, as disclosed or evidenced: **Affiliates:** Ottogi (frozen pizza; Ottogi-brand New Sugar and yeast) [TW]. **Pizza franchises:** for example Pizza Alvolo, which audited Choheung's Ansan cheese plant and planned to raise volumes to about 30 tonnes per month [INS]. **Bakeries and coffee chains:** the principal outlets for bakery ingredients per the business-report summary [VL]. **Food-service distributors and B2B e-commerce:** Codano SKUs are resold by distributors including Hyundai Green Food on the Foodspring marketplace [FS]. **Confectionery and food manufacturers:** users of yeast, creams and sweeteners [MS]. ### End-markets Korean bakery and confectionery, pizza food-service (franchise and independent), retail frozen convenience foods (via Ottogi), and home meal replacement. Exports were negligible in FY2025 (about KRW 0.08bn of KRW 488.2bn) [VL]. ### Independent characterisation Choheung is best understood as a captive, volume-driven processor rather than a consumer brand owner. Its growth since 2021 has come from cheese throughput and pizza contract volumes, not pricing power. The business is working-capital-intensive because imported cheese is bought in bulk and funded by short-term (largely trade-type) borrowings. Profitability therefore swings with three exogenous variables: global dairy prices, the KRW/USD and KRW/NZD exchange rates, and Korean short-term interest rates. The parent relationship provides demand visibility and distribution, but limits strategic independence and minority-shareholder upside.

Revenue$0.3B
Employees533
Market CapN/A
Founded1959
Ansan, South Korea
ChoA

ChoA Pharmaceutical Co., Ltd.

Premium
Information Technology

ChoA Pharmaceutical is a small, family-controlled Korean consumer-health manufacturer built on pharmacy-channel over-the-counter (OTC) medicines and health functional foods. It was founded in 1988 by Cho Won-ki, a pharmacist who had run a pharmacy for two decades before he acquired Samkang Pharmaceutical. Its identity rests on drinkable ampoule formats: it introduced Korea's first "double-neck" ampoule in 1995 and today makes about 200 medicines and health foods, including some 30 ampoule products such as Hepos/Hepatos (liver), Fematin (anaemia), Joa Viton (memory/endurance) and the Jalkton children's nutrition line. The model favours pharmacist education and direct pharmacy trade over mass advertising, supported by the affiliated Medipharm chain. Exports reach about 23 countries, led by Southeast Asia. Since 2019 the company has posted seven straight years of operating losses. Its equity has eroded close to share capital, and in 2026 it consolidated shares 5:1 to avoid new KOSDAQ "penny stock" delisting rules. By Q2 2026 it was near operating breakeven, helped by exports. --- ### What the company does ChoA manufactures and sells finished-dose medicines and consumer health products, mainly in Korea. Morningstar's profile lists treatments for diarrhoea, duodenal and gastric ulcer, gastritis, cough and cold, plus nutrition products, health drinks and mixed drinks for children. The company says its range covers general and specialised medicines, health supplements and pet products, aimed at children, women and the elderly (company profile via Datanyze). Its core technical competence is liquid oral dosage in single-dose ampoules. The company states it produces about 200 medicines and health foods, including about 30 drinkable ampoule products such as Hepos, Fematin, Vasoclean and Mabis (company "About CHO-A" page). In 2022 it developed and patented a polypropylene ampoule, "CHO-A Safeasy". Patents were filed in 12 overseas jurisdictions, with commercial production from May 2023 (Hankyung, Aug 2022; company history). ### Business and revenue model | Revenue component | Description | Evidence | |---|---|---| | Own-manufactured products (제품) | OTC medicines, health functional foods, children's drinks and ampoule products made at Haman | 81% of revenue in Q2 2026 (Butler, from DART) | | Merchandise (상품) | In-licensed or purchased-for-resale products, e.g. Liposome Vitamin C 1000, sold under exclusive Korean distribution from Cure Support (Netherlands) | 19% of revenue in Q2 2026 (Butler); Dealsite, 4 Aug 2026 | | Product exports | Own products shipped to about 23 countries | 15.5% of H1 2026 revenue (DailyPharm, 14 Sep 2026) | | Contract manufacturing (CMO/OEM) | Third-party manufacturing, especially ampoules | Named as one of four 2026 core strategies (DailyPharm, Feb 2026); revenue not separately disclosed | | E-commerce / home-shopping | Health functional foods sold through partners on TV home-shopping and online | Medigate/Hankyung, Aug 2022; "e-commerce channel diversification" is a 2026 strategy | | Animal health | Animal medicines and supplements; business purpose added at the March 2024 AGM; launched 2025 | Dealsite, Mar 2024 / Apr 2025; Kormedi, Feb 2026 | The revenue model is entirely product sales. There is no subscription or recurring licensing revenue. ### Value-chain position and customers ChoA sits in finished-dose formulation, manufacturing and branded distribution. It buys active pharmaceutical ingredients (APIs) and excipients externally; the 2024–25 Galeo stock-out was traced to a process problem with a European API supplier (DailyPharm, Mar 2025). Domestic customers are mainly community pharmacies, served through direct trade. The company says it holds to direct dealing for OTC items, and has ties with Medipharm, a chain of about 1,000 pharmacies (DailyPharm, 2017). Some prescription (ETC) items are made by contract manufacturers and sold through wholesalers (DailyPharm, 2017). Overseas customers are distributors and importers in Southeast Asia, China, the US, Central Asia, Latin America and Africa. One aggregator (Bullstory) describes a high share of hospital injectables and prescription drugs. Company statements and trade press consistently describe an OTC-centred model, and the company itself said in 2011 that it had no prescription drugs. Bullstory's characterisation is treated as inaccurate. ### Company's own description In its FAQ the company says it wants people everywhere to receive quality treatment regardless of status or location. Its mission is to deliver good-quality drugs at a fair price, working with reliable manufacturers, distributors and wholesalers, under the motto "Keep people happy and healthy, far away from diseases." It also states that all its facilities are located in South Korea. In explaining what sets it apart, it cites an indirect marketing approach that educates pharmacists and doctors rather than relying on mass advertising (company FAQ). ### Independent characterisation ChoA is a micro-cap, legacy pharmacy-OTC house. Its brands are well known (sports sponsorship, notably the long-running CHO-A Pharm Professional Baseball Award), but none of its products has reached the KRW 10 bn "leading OTC" scale. In 2017 management itself said it lacked a KRW 10 bn+ product (DailyPharm, 2017). Its cost structure is poorly matched to its revenue base. SG&A was about 49% of revenue in 2024, and cost of sales plus SG&A exceeded revenue by 15% (Dealsite, Apr 2025). The many-products, small-batch manufacturing model is exposed to raw-material inflation, generic competition and Korean drug-price cuts. Management named these factors in explaining its 2025 results (Kormedi, Feb 2026). The 2026 turnaround rests on three things: export growth (Southeast Asia, Latin America, Africa), deep SG&A cuts, and capital-markets measures to stay listed. It is real but early, and the improvement is two quarters old.

Revenue$0.0B
Employees275
Market CapN/A
Founded1988
Seoul, South Korea
Chips&Media

Chips&Media, Inc.

Premium
Information Technology

Chips&Media is Korea's longest-established listed semiconductor-IP licensor. It is also the only one with a consistent operating profit. **What it does:** It specialises in hardware video codec IP — encoders and decoders for H.264/AVC, H.265/HEVC, AV1 and now AV2 and APV. Chip designers embed these blocks in their systems-on-chip. **Business model:** A pure-play licensing model with zero cost of goods sold. Revenue combines up-front licence fees with per-unit royalties that begin two to four years later, once customers' chips reach mass production. **Scale:** More than 150 customers and roughly 2 billion cumulative chips shipped with its IP. **Customers:** They include Google ("G"), Qualcomm, NXP, AMD, Meta, Ambarella and Chinese AI-SoC developers. **Revenue mix (FY2025):** Industrial (CCTV/server) 48%, automotive 31%, home entertainment 13% and mobile 8%. By region, China was 39% and the US 37%. **Diversification:** Since 2023 it has pushed into AI imaging with the WAVE-N video-specialised NPU and a software-defined AI ISP. **Scale constraint:** At about KRW 28.5bn of revenue (FY2025), it is a niche specialist. **Competition:** It competes chiefly with China's VeriSilicon and France's Allegro DVT, as well as with in-house teams at large SoC vendors. --- ### What the company does Chips&Media develops and licenses semiconductor intellectual property (silicon IP). These are pre-designed, pre-verified functional blocks that fabless chip companies and integrated device manufacturers integrate into their SoCs. The company's core block is the hardware video codec: - the encoder, which compresses video for recording or transmission; - the decoder, which decompresses video for playback. KIRS (Mar 2025) describes the firm as a silicon-IP specialist founded in 2003 whose main business is video IP development and sales. It notes that the company first licensed video IP to a domestic customer in 2004, to an overseas customer in 2005, and earned its first royalty in 2006. Its own boilerplate (Feb 2026 release) describes it as a multimedia IP provider offering: - hardware video codec IP; - an image-processing NPU; - lossless and lossy frame-buffer compression IP. The release says the NPU is transforming it into a "premium multimedia IP provider". ### Business and revenue model | Revenue stream | Recognition trigger | Typical economics (as disclosed / reported) | FY2025 share | |---|---|---|---| | Licence | Delivery of IP design to the customer at the start of chip development | Typical contract KRW 0.5–1.0bn; occasional deals above KRW 1bn; newer codecs command higher prices (KIRS) | 59.9% (KRW 17.1bn) | | Royalty | Customer's chip sales; settled quarterly | Industry-average figure of about KRW 50 per chip (KIRS); begins about 2–3 years (KIRS) or 3–4 years (Eugene) after licence | 35.3% (KRW 10.1bn) | | Service | Paid technical support and customisation | Ancillary to licences | 4.7% (KRW 1.4bn) | Revenue has three streams (KIRS, Mar 2025; Eugene). **Cost structure:** - Cost of goods sold is zero. - All expenses are SG&A, which is dominated by R&D personnel. - Gross margin is therefore 100%, and operating leverage is high. **Lag between licences and royalties:** Licence wins are a leading indicator of royalties several years later. Eugene (Feb 2026) explicitly frames the 2022–2023 dip in licence counts as the cause of the soft royalty line in 2024–2025. ### Value-chain position Chips&Media sits at the top of the system-semiconductor value chain: - alongside EDA vendors (Synopsys, Cadence) and CPU-IP vendors (Arm); - upstream of fabless designers, design-service partners (DSPs/VCAs), foundries and OSATs. KIRS cites an industry estimate that about 80% of SoC IP is still developed in-house and about 20% is bought from third parties. It argues that the third-party share should rise as codec standards multiply (AV1, AV2, APV, VVC). ### Customer types and end-markets **Customer types:** - global fabless and IDM chipmakers (Qualcomm, NXP, Ambarella, a Japanese top-3 automotive chipmaker); - big-tech captive-silicon teams (Google, Meta, AMD per the CEO's 2024 interview); - Chinese AI-SoC, data-centre and robotics chip developers (Hanwha, Aug 2026). **Customer counts:** More than 150 customers (company, 2024). About 130 royalty-paying customers in 2024 (Alpha Distillery). Exports exceed 90% of sales. **End-markets (company classification):** - Industrial (surveillance/CCTV, data-centre/server video and AI SoCs); - Automotive (ADAS cameras, infotainment); - Home Entertainment (TV, set-top box); - Mobile (smartphone application processors). ### Independent characterisation Chips&Media is a high-quality but sub-scale niche monopolist-in-a-duopoly. Its strengths are: - technical leadership in multi-standard video codecs; - silicon-proven reliability, with more than 2bn units shipped; - a debt-free balance sheet with net cash of about KRW 30–50bn. Its constraints are: **Lumpiness:** The licence model produces volatile quarterly results. Q1 is seasonally weak and Q4 strong. **Concentration:** Revenue is concentrated in China and the US, both politically exposed. **Limited AI share:** The AI-imaging diversification (NPU, AI ISP) remains a small share of revenue. The investment narrative in 2025–26 rests on three things: - conversion of record licence volumes into a royalty upcycle, led by Google mobile royalties since 3Q25; - next-generation codec wins (AV2, APV/WAVE-P); - corporate-control optionality, given that the private-equity largest shareholder reportedly explored a sale in 2026.

Revenue$0.0B
Employees83
Market CapN/A
Founded2003
Seoul, South Korea
Chinyang

Chinyang Poly Urethane Co., Ltd.

Premium
Information Technology

Chinyang Poly Urethane is a small-cap Korean manufacturer of flexible polyurethane (PU) foam, chiefly slabstock ("soft slab") foam. Its foam is cut and converted into intermediate materials for bedding, furniture and upholstery, apparel, footwear, automotive interiors, packaging, construction and electronics. The company has operated since 1975 from Pyeongtaek in Gyeonggi province and reports a single business segment, PU foam (100% of Q2 2026 revenue per butler.works). FY2025 revenue was KRW 46.6 bn and operating profit KRW 1.8 bn, both down sharply from FY2024. It is 50.5%-owned by Chinyang Holdings and sits within a family-controlled chemicals group that also includes polyol producer KPX Chemical upstream. In 2025–2026 the company began a debt- and equity-funded expansion: a new plant in Eumseong (North Chungcheong), automated foaming lines, and a foam-scrap recycling loop (R-PUF / Re-Polyol). These moved it from a low-leverage, high-payout profile to one of elevated leverage and execution risk. --- ### What the company does Chinyang Poly Urethane manufactures and sells polyurethane foam. Its core product is flexible slabstock PU foam: large continuous blocks produced by reacting polyols with isocyanates (typically TDI for flexible foam) plus blowing agents, catalysts and additives. The blocks are cured and then cut or processed into sheets, rolls and shaped parts to customer specification. Third-party profiles derived from DART describe the main product as urethane flexible slab foam used as an intermediate material in bedding, apparel, footwear and automotive interiors (mydailybyte.com company overview). Morningstar describes polyurethane supplied into cars, furniture, beds and electronics. Cbonds lists end uses including apparel, furniture, upholstery, automotive seats, insulating materials, electronics and footwear. ### The company's own description The January 2026 IR presentation (prepared jointly with Chinyang Holdings) frames the business around three themes: - a PU-foam-centred revenue structure that delivers predictable results; - a diversified customer base that stabilises sales; - core PU foam technology applied across household (living), industrial and automotive uses. The same presentation describes the limits of the conventional PU foaming and curing process and the move to automated foaming equipment. It also presents a closed-loop recycling scheme ("R-PUF"): foam scrap from cutting and processing is recovered and converted into recycled polyol ("Re-Polyol"), then fed back into foaming alongside virgin raw materials (Chinyang IR presentation, 8 Jan 2026). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue mix | Essentially 100% product sales of PU foam (butler.works, Q2 2026 segment data). No subscription, licensing or service revenue is disclosed. | | Value-chain position | Midstream converter. It buys polyol and isocyanate chemicals from upstream petrochemical producers and sells foam blocks or cut foam to downstream manufacturers (mattress, furniture, footwear, apparel, automotive interior and packaging makers). Named suppliers and customers are not publicly disclosed in sources reviewed. | | Customer type | B2B industrial and consumer-goods manufacturers. No direct-to-consumer brand is disclosed. | | Geographic focus | Predominantly domestic Korean manufacturing and sales. Export share is not publicly disclosed in sources reviewed. | | Cost structure | Raw-material intensive (polyols and TDI are petrochemical derivatives). FY2025 payroll was 8.8% of revenue. Depreciation was about KRW 1.6 bn in FY2025 (Valueline cash-flow data). | | Other income | One aggregator (bullstory.io) mentions real-estate leasing as an activity. | ### Independent characterisation The company is a small, capital-light (until 2025), single-product foam converter whose earnings depend on volume demand from Korean bedding, furniture, footwear and automotive-interior production, and on the spread between foam selling prices and petrochemical input costs. Historically it produced steady operating profits of KRW 3–5 bn on revenue of KRW 50–55 bn, generated positive operating cash flow of about KRW 5 bn a year, and paid most of it out as dividends. Since 2024 the profile has changed materially. Property, plant and equipment rose from KRW 39.1 bn (end-2023) to KRW 92.1 bn (June 2026), and total borrowings from KRW 10.0 bn to KRW 48.7 bn. This funded land acquisition and plant construction in Eumseong. A KRW-denominated rights offering completed in March 2026 increased the share count by about 40%. The investment case now rests on whether the new capacity, automation and recycling capability can lift volumes and margins enough to service the debt. Q2 2026 results (revenue KRW 14.9 bn, operating profit KRW 1.8 bn) were the first sign of margin recovery. ### End-markets served | End-market | Evidence | Notes | |---|---|---| | Bedding / mattresses | mydailybyte (DART-derived), Morningstar | Typically the largest use of flexible slabstock foam globally. Company-specific share not disclosed. | | Furniture / upholstery | Morningstar, Cbonds, bullstory | — | | Footwear | mydailybyte, Cbonds, etfshopping | etfshopping mentions shoe soles. Slabstock foam is more typically used in insoles and linings. | | Apparel | mydailybyte, Cbonds | Foam laminates and pads | | Automotive interiors / seats | mydailybyte, Cbonds, IR deck ("automotive") | — | | Electronics | Morningstar, Cbonds | Cushioning and gasketing | | Construction / insulation | Cbonds, bullstory | — | | Packaging | bullstory | — |

Revenue$0.0B
Employees90
Market CapN/A
Founded1975
Pyeongtaek, South Korea
Chinyang

Chinyang Holdings Corp.

Premium
Information Technology

Chinyang Holdings is the intermediate holding company of the "Chinyang" half of the KPX Group. It sits beneath KPX Holdings, which in turn is controlled by the founding Yang family. The parent has only four employees and runs no production of its own. Its consolidated revenue of about KRW 280bn comes from roughly seven subsidiaries and five sub-subsidiaries in three activities: **Automotive interior parts (about 52% of revenue):** headliners and carpets from Chinyang Automotive, plus seat foam. **Synthetic resin products (about 47%):** polyurethane slab and moulded foam, and PVC synthetic leather and tarpaulin. **Real-estate leasing (about 1%):** revenue is small, but the land holdings are large. It is a low-margin, domestically focused, commodity-linked portfolio: the consolidated operating margin has fallen from 8.6% (FY2016) to 1.3–2.1% (FY2023–FY2025). Even so, the company pays a high, steady dividend (KRW 200 per share for FY2022–FY2025) and trades at about 0.4x book value. Large non-operating gains, from asset revaluations, disposals and investment income, regularly push net profit well above operating profit. --- ### Company's own description (paraphrased from the latest Business Report summary) Chinyang Holdings describes itself as a holding company whose main business is controlling domestic companies through share ownership [S7]. It was created in January 2008 by splitting off and merging the investment divisions of Chinyang Industrial, Chinyang Chemical and Chinyang Polyurethane. As of September 2025 it held 7 subsidiaries and 5 sub-subsidiaries [S7]. The main subsidiaries named are: - Chinyang Industrial - Chinyang Polyurethane - Chinyang Chemical - Chinyang Automotive - Chinyang Energy Utility - Chinyang AMC - Chinyang Mulsan Management presents the holding structure as a means to several ends [S7]: - concentrate on core businesses through selection and focus; - pursue new businesses and M&A; - expand overseas; - establish responsible management and improve efficiency; - simplify governance and improve capital efficiency. The company also states that it complies with Korea's Fair Trade Act holding-company requirements: subsidiary shareholdings worth at least 50% of total assets, and a debt ratio of no more than 200% [S7]. ### Independent characterisation Economically, Chinyang Holdings is three different businesses held in one consolidated balance sheet. 1. **Tier-2/3 automotive interior supplier, reaching Hyundai Motor Group volumes indirectly.** - Chinyang Automotive makes headliners and interior carpets. FY2025 standalone revenue was KRW 127.7bn, with an operating loss of KRW 1.7bn [S21]. - Chinyang Industrial makes polyurethane foam used in car seats and interiors [S18]. - Chinyang Chemical's PVC synthetic leather goes into car seats, door trims, consoles and headrests. It reaches Hyundai and Kia through tier-1 converters, historically Kolon Glotech [S15][S17]. 2. **Converter of polyurethane and PVC.** - Chinyang Polyurethane makes flexible polyurethane slab foam for bedding, apparel, footwear and car interiors [S20]. - Chinyang Industrial makes polyurethane foam materials [S18]. - Chinyang Chemical makes PVC synthetic leather and tarpaulin (and historically flooring) [S15][S17]. - All three buy petrochemical inputs (polyols, isocyanates, PVC resin, plasticisers) and convert them into intermediate goods. Margins therefore depend on raw-material and FX swings and on how much bargaining power the customers have [S18][S29]. 3. **Real-estate and financial-asset holder.** - Chinyang Mulsan (KRW 192.5bn of total assets) and Chinyang AMC (KRW 55.5bn) are the two largest subsidiaries by assets, yet contribute little revenue [S2]. - The group also holds land worth KRW 138.2bn at book value inside PP&E and KRW 64.0bn of investment property (30 Jun 2026) [S5]. - It owns stakes in several venture or IPO private funds [S2]. - This asset layer produces the recurring non-operating gains that dominate reported net income. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product sales (B2B manufacturing); small leasing income; dividend and investment income at the parent | | Product vs service vs subscription vs licensing | About 99% product, about 1% leasing (2Q26 mix) [S9]; no subscription or licensing revenue disclosed | | Value-chain position | Midstream converter: petrochemical inputs → foam, artificial leather and interior parts → tier-1 module makers or automakers, bedding and furniture makers, footwear makers | | Customer types | Tier-1 auto interior module suppliers; automaker vendors; bedding, apparel and footwear manufacturers; construction-material distributors (historical flooring) | | End-markets | Korean automotive production (dominant); bedding and furniture; footwear; construction and interiors | | Geography | Revenue generated almost entirely in Korea [S29]; a geographic split is not disclosed | | Raw-material exposure | Polyols, TDI/MDI, PVC resin and plasticisers, priced off international petrochemical markets [S17][S18] |

Revenue$0.2B
Employees4
Market CapN/A
Founded2008
Busan, South Korea

Page 79 of 482

1…787980…482

Page 79 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo